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Purpose: The delivery of post-mastectomy radiotherapy (PMRT) can be challenging for patients 
with left-sided breast cancer due to the planning target volume (PTV) size and proximity to 
critical organs. This study investigates the use of protons, both passively scattered (PS) and 
intensity modulated proton therapy (IMPT), for PMRT in a clinically-representative cohort of 
patients, and quantitatively compares the predicted outcomes of volumetric modulated photon 
arc therapy (VMAT) to those of proton therapy to develop an evidence-based rationale for 
selecting a treatment modality for PMRT patients. 
Methods: Eight left-sided PMRT patients previously treated at our clinic with VMAT were 
included in this study. PTVs included the chest wall and regional lymph nodes. PS and IMPT 
plans were constructed using a commercial proton treatment planning system. The resulting 
plans were compared to the corresponding VMAT plans on the basis of PTV coverage; dose 
homogeneity index (DHI) and conformity index (CI); dose to organs at risk (OAR); tumor 
control probability (TCP), normal tissue complication probability (NTCP) and secondary cancer 
complication probability (SCCP). The impact of range, set-up errors, and sensitivity of dose-
response models was also evaluated. Statistical significance between VMAT and each proton 
modality was tested using the paired Student’s t-test (p<0.05). 
Results:  All modalities produced clinically acceptable PMRT plans with nearly 100% TCP. The 
proton treatment plans provided significantly lower NTCP values for the heart and the lung while 
maintaining significantly better CI and DHI values. At a prescribed dose of 50.4 Gy (RBE) in the 
PTV, the mean NTCP value for the patients decreased from 0.83%±0.67% to <0.05%±0.05% for 
the whole heart (cardiac mortality) and from 2.05%±0.23% to <1% for the lungs (radiation 
pneumonitis) for VMAT and proton plans, respectively. Proton therapy NTCP and SCCP values 
xii 
 
were consistently lower than those of VMAT regardless of biological parameter values. Target 
coverage for VMAT and IMPT plans was most sensitive to positional uncertainties.  
Conclusions:  All three techniques (VMAT, PS, and IMPT) provide acceptable PMRT treatment 
plans for each patient in this study. However, proton therapy showed significant advantages in 





Chapter 1 Introduction 
1.1 Background 
According to the Surveillance Epidemiology and End Results database (2013), breast 
cancer is the most common cancer, other than non-melanoma skin cancer, among women in the 
United States, with 1 in 8 women diagnosed in their lifetime. Breast cancer is the second leading 
cause of cancer deaths among women. The majority of women will be diagnosed with invasive 
breast cancer and there are about 2.8 million breast cancer survivors in the United States. 
Women between the ages of 55 and 64 have the highest incidence rate of breast cancer.   
 The female breast is made up mainly of lobules, ducts, and stroma. The majority of breast 
cancers, 50% to 75%, begin in the milk ducts, with the most common ductal cancers being ductal 
carcinoma in situ or DCIS. This type of cancer happens when abnormal cells grow inside the 
ducts, but have not spread to nearby tissue or beyond. DCIS is also referred to as a non-invasive 
cancer. If the abnormal or cancer cells have spread to nearby tissues outside of the ducts then it is 
called an invasive or infiltrating ductal carcinoma. DCIS, if left untreated, will likely become 
invasive. In fact, 80% of invasive cancers are invasive ductal carcinomas. The remaining 
percentage of breast cancers are mainly lobular cancers and may be invasive or non-invasive 
(Dillon et al., 2010). 
Due to the high incidence and morbidity rates of breast cancer, great strides have been 
made in the early detection and treatment of breast cancer. Treatment of breast cancer includes 
any combination of surgery, radiation therapy, and chemotherapy.  According to the National 
Comprehensive Cancer Network (NCCN, 2014), most breast cancer patients will have surgery, 
e.g. a lumpectomy or a mastectomy. A mastectomy can be a radical mastectomy, modified 




mastectomy which removes the entire breast and all of the axillary lymph nodes, but the 
pectoralis muscles remain intact. A mastectomy is highly recommended (NCCN, 2014), if the 
following qualities describe the patient: signs of cancer throughout the breast and regional lymph 
nodes, tumors larger than 5 cm that cannot be reduced by neoadjuvant therapy, or previous 
history of radiation therapy to the breast.  
 
1.2 Post-Mastectomy Radiotherapy 
After the mastectomy, it is common for the patient to undergo chemotherapy and/or 
radiotherapy to treat subclinical disease that may remain. Previous studies have shown 
significant improvement in the overall and local survival rates for patients who received 
radiotherapy after a mastectomy (Overgaard et al., 1997; Ragaz et al., 1997; Overgaard et al., 
1999). Specifically, three recent randomized trials have demonstrated a 9% benefit in survival 10 
to 15 years in patients randomized to comprehensive locoregional radiotherapy after 
chemotherapy or hormonal therapy. Radiotherapy was delivered to the chest wall and regional 
nodes, including the internal mammary nodes, in these studies (Overgaard et al., 1997; Ragaz et 
al., 1997; Overgaard et al., 1999). The extent of radiotherapy after mastectomy is based on how 
many lymph nodes have cancer and the size of the primary tumor. The National Institutes of 
Health consensus panel and the NCCN (2014) recommend post-mastectomy radiotherapy 
(PMRT) in patients with 4 or more positive axillary lymph nodes or T3 (>5cm diameter) or T4 
(spread to chest wall) staged lesions (Eifel et al., 2001). And strong consideration of PMRT 
should be given to patients with 1 to 3 positive axillary lymph nodes (NCCN, 2014). 
Post-mastectomy irradiation should be performed with CT-based treatment planning to 
limit radiation dose to the heart, lungs and other critical structures. The recommended radiation 




regional lymph nodes. Figure 1.1 depicts a typical treatment area for PMRT. This area includes 
the chest wall (CW), axillary lymph nodes (AX), supraclavicular lymph nodes (SC), and internal 
mammary lymph nodes (IMN). Chest wall has the greatest risk of cancer recurrence in patients 
undergoing mastectomy and is given dose coverage priority (NCCN, 2014). 
 
Figure 1.1 Radiation treatment field from beam's eye view of a post-mastectomy radiotherapy 
patient. 
 
1.2.1 Common PMRT Treatment Techniques 
Post-mastectomy radiotherapy was historically delivered by conventional mixed-beam 
technique, where low energy electrons were used to treat the medial CW and IMN and oblique 
electrons to treat the lateral CW. The SC and AX nodes were treated with either anterior or 
parallel-opposed x-rays (Pierce et al., 2002; Ashenafi et al., 2010). However, this technique 
causes hot-spots or excess dose in the regions where the fields abut. Controlling this dose 
inhomogeneity requires careful dosimetry planning such as matching the penumbras of the 
beams with each other and feathering the junction during treatment to spread the hot spot out 
over a larger area (Ashenafi et al., 2010). Each of these techniques requires significant effort 




 The previously mentioned treatment problems associated with field junctioning can be 
reduced by using static or dynamic intensity modulated radiation therapy (IMRT) techniques 
(Ashenafi et al., 2010). Such techniques used to treat PMRT include static IMRT, Helical 
Tomotherapy (HT), and Volumetric Modulated Arc Therapy (VMAT) (Ashenafi et al., 2010; 
Teoh et al., 2011). HT was compared to the conventional mixed beam radiotherapy for post-
mastectomy patients by Ashenafi et al. in 2010 and HT achieved significantly better PTV 
coverage and sparing of organs at risk.  However, HT resulted in increased dose to the 
contralateral breast as well as larger volumes of low dose to normal tissues.  
 
1.2.2 Volumetric Modulated Arc Therapy 
Unlike HT, VMAT is performed using a standard linear accelerator by rotating the gantry 
in a 360˚(max) arc(s). The modulated portion of the planning is accomplished by varying the 
multileaf collimator leaf position along with the dose rate and gantry rotation speed 
simultaneously during the treatment delivery. Currently there are several arc-based IMRT 
systems available including RapidArc by Varian, SmartArc by Phillips, and Elekta VMAT by 
Elekta. A study performed by Nichols et al. (2012) compared VMAT and HT for 15 PMRT 
patients, and found that both modalities provided clinically acceptable treatment plans, with 
VMAT achieving better conformity index and low-dose OAR sparing while HT achieved better 
dose homogeneity. The study also showed VMAT required less treatment time compared to HT. 
This is particularly advantageous to reduce treatment errors associated with intrafraction patient 
motion, both internal and external. Another benefit of VMAT over HT is the ability to deliver the 
radiotherapy plan using a conventional linear accelerator, provided the systems have been 
configured for VMAT capability (Teoh et al., 2011). This usually includes a software upgrade as 




1.3 Complications of PMRT 
While VMAT can provide clinically acceptable PMRT plans, there is still an increase in 
low dose radiation to the surrounding normal tissues (Teoh et al., 2011). This increase in low 
dose to the normal tissues can lead to radiation induced complications especially in organs with 
strong dose-volume response such as the heart and lungs (Pierce et al., 2002). There are two 
categories of complications that occur after radiation treatments, acute and late effects.  
Acute effects occur during or shortly after the radiation treatments. Common acute 
effects that occur for PMRT include skin irritation, radiation pneumonitis, hair loss, nausea, and 
fatigue (Macdonald et al., 2013b). Late effects are characterized as occurring months, years, or 
even decades after radiation treatments. Late effects for PMRT include pericardial disease, 
congestive heart failure, secondary malignant neoplasms, and coronary atherosclerosis 
(Macdonald et al., 2013b).  
Radiation pneumonitis occurs in 1 to 5% of patients treated for breast cancer (Marks et 
al., 2010) or as high as 14.6% with concurrent chemotherapy (Macdonald et al., 2013a). 
Radiation pneumonitis is the inflammation of the lungs due to radiation therapy and most 
commonly occurs between 1 to 6 months after completing treatment and has five grades of 
severity. Usually Grade 2 or higher is considered clinically relevant (Graham et al., 1999). 
Radiation pneumonitis is known to have a dose-volume response and therefore limits the 
maximal safe radiation dose that can be delivered to the chest wall (Seppenwoolde et al., 2003; 
Marks et al., 2010). It is essential to minimize the dose delivered to the lungs while maximizing 
the dose to the target volume (Marks et al., 2010). 
Second malignant neoplasms (SMNs) and cardiovascular disease (CVD) are two of the 




et al., 2011). Radiotherapy-associated CVD refers to a wide spectrum of diseases. Ischemic heart 
disease is one such CVD that arises from PMRT with the risk being higher for women treated for 
left-sided breast cancer than right-sided (Darby et al., 2013). Darby et al. (2103) found that the 
risk of a major coronary event increases linearly with the mean dose to the heart with a risk value 
of 7.4% per gray, with no apparent threshold. The risk of radiation-induced cardiovascular 
disease begins to increase 5 to 10 years after irradiation and is progressive with time 
(Andratschke et al., 2011; Darby et al., 2013). Other breast cancer studies have shown a 
statistically significant increase in coronary artery disease and/or nonfatal myocardial infarction 
associated with left-sided radiotherapy compared with right-sided radiotherapy or no 
radiotherapy (Travis et al., 2011). These complications are of great concern because although 
local control rates are increasing with better radiotherapy techniques the survival benefit is offset 
by an increase in deaths from cardiovascular disease (Andratschke et al., 2011). About 1% more 
deaths due to causes other than breast cancer were observed among patients having received 
loco-regional post-mastectomy radiotherapy due primarily to radiogenic cardiac complications 
and to a lesser extent secondary malignancies, particularly pulmonary (Weber et al., 2006). 
Photon breast cancer radiotherapy has also been associated with a small but incremental increase 
of long-term risk of contralateral breast cancer in a large SEER series and data stemmed from 
randomized trials conducted by the Early Breast Cancer Trialists’ Collaborative Group overview 
(Gao et al., 2003). 
 
1.4 Proton Therapy  
Comparative treatment planning studies have consistently shown proton beam therapy 
can substantially decrease dose to OARs for the treatment of early or locally-advanced breast 




Macdonald et al., 2013a). In a study by Johansson et al. (2002) passively scattered proton 
therapy appeared to have major advantages in terms of lower complication risks for cardiac 
mortality and radiation pneumonitis when compared with treatments using conventional 
radiation techniques for treating node-positive left-sided breast cancer after breast-conserving 
surgery. In another study, Ares et al. (2010) found intensity modulated proton therapy was 
advantageous for complex left-sided whole breast target volumes, patients with unfavorable 
thoracic anatomy or placement of intrathoracic organs, and for patients with reduced organ 
tolerance from pre-existing cardiac or pulmonary diseases compared to 3D conformal 
radiotherapy and static multi-field IMRT. Proton therapy has also recently emerged as a new 
PMRT technique. MacDonald et al. (2013) completed the first known clinical investigation of 
passively scattered proton therapy for PMRT and assessed the patients for skin toxicity, fatigue 
and radiation pneumonitis while late effects were not reported. The study reported that passively 
scattered proton RT is feasible, well tolerated, and advantageous for patients with unfavorable 
cardiac anatomy.  
The advantage seen with proton therapy mentioned above is attributed to the physical 
properties of the charged particle. Protons, at therapeutic energies (70-250 MeV), interact almost 
exclusively with atomic electrons via Coulombic collisions, yielding nearly straight trajectories 
culminating in a rapid increase in energy loss rate near the end of range (Bragg peak). Since 
protons lose the majority of their energy near the end of range, there is nearly zero exit dose 
(ICRU, 2007). This sharp distal dose distribution is a major reason for using protons for 
radiotherapy.  
There are two main methods for proton radiotherapy delivery: passive and active 




passive beam setup uses a double-scattering system to spread the beam laterally, a block to shape 
the beam laterally, a rotating variable-thickness propeller to spread out the Bragg peak in depth, 
and a field-specific collimator to shape the dose distribution to the distal edge of the target 
(ICRU, 2007). Active beam-scanning systems can position a single narrow Bragg peak from a 
near monoenergetic proton beam anywhere in the patient. Lateral positioning of the Bragg peak 
is accomplished by scanning magnets, and penetration depth is controlled by changing the 
energy at the nozzle entrance. The ability to control the Bragg peak placement within the patient 
allows the implementation of intensity modulated proton therapy (IMPT). In IMPT a narrow 
beam (spot) is moved laterally across the tumor and its intensity can be modulated according to 
the beam energy and position. The weights of all these beam spots is calculated by the proton 
treatment planning optimizer, much like IMRT techniques in photon therapy (Mohan et al., 
2010).  
 








1.5 Statement of the Problem 
Post-mastectomy radiotherapy improves local tumor control however; toxicities associated 
with this treatment can be significant due to the complex target volume and proximity of normal 
tissues. Therefore, the challenge with planning PMRT using any modality is reducing the dose to 
the organs at risk while not compromising target coverage. Previous studies have shown that 
both VMAT and proton PMRT can accomplish the necessary target coverage while minimizing 
the dose to organs at risk (Weber et al., 2006; Ares et al., 2010; Macdonald et al., 2013b; 
Nichols et al., 2014). Several comparative planning studies hypothesize that protons will provide 
a decrease in acute and late cardiopulmonary toxicities for patients requiring radiotherapy for 
advanced or left-sided breast cancer compared to conventional and IMRT photon techniques 
(Lomax et al., 2003; Weber et al., 2006; Ares et al., 2010). However, no study has compared 
VMAT and proton modalities for PMRT to compare the predicted risks of late effects. The goal 
of this study sets out to accomplish such a comparison for left-sided post-mastectomy patients.  
 
1.6 Hypothesis and Specific Aims 
We proposed to test the following hypothesis: For a clinically representative cohort of 
post-mastectomy patients, passively scattered and intensity modulated proton therapy can 
improve normal tissue sparing while maintaining equal or better target coverage than volumetric 
modulated arc therapy photon plans ultimately resulting in significantly lower (p<0.05) predicted 
risks of late effects for the heart, lungs, and contralateral breast. 
 To test this hypothesis, we compared photon and proton PMRT treatment plans on the 
basis of dosimetric and radiobiological endpoints, along with the uncertainties associated with 
each such calculation for eight randomly selected left-sided PMRT patients previously treated 




field. We estimated the risk of radiogenic second cancers, lung toxicity, and cardiac toxicity for 
all. To accomplish these goals, we proposed the following specific aims: 
Aim 1: Determine if the mean dose-volume treatment plan metrics between VMAT, 
passively scattered proton therapy and intensity modulated proton therapy are 
statistically significantly different from each other for a clinically representative 
sample of patients. 
Aim 2: Determine if 1) tumor control probability, 2) normal tissue complication 
probability for whole heart, myocardium, and lungs, and 3) the second cancer 
complication probability for contralateral breast and lungs between VMAT and 
proton therapies are statistically significantly different from each other. 
Aim 3: Evaluate impact of positional uncertainty, proton range uncertainty, and dose-
risk model sensitivities on dosimetric and radiobiological results from Aim 1 and Aim 




Chapter 2 Methods 
2.1 Patient Selection 
 Eleven patients that received a left-sided modified radical mastectomy and volumetric 
modulated arc therapy radiation treatments at Mary Bird Perkins Cancer Center from June 2013 
to November 2013 were consecutively identified. All patients were treated by the same radiation 
oncologist and fell within the age range of 20 to 80 years. Eight of these eleven patients were 
selected for the study. Three patients were excluded from the study due to the presence of a 
chemotherapy port within the treatment site, an immediate reconstruction of the left breast, or 
data transfer errors. 
Once the patients were selected from the photon treatment planning system to be 
transferred to the proton treatment planning system, sensitive patient information was 
anonymized. Each patient was assigned a research number in the format CW-X, where x is an 
index from 1 to 8. In the proton TPS, the patient’s last name and medical record number (MRN) 
were replaced by this research number, and all other personally identifiable information was 
deleted. Table 2.1 lists the cases used for this study, indicating subjects’ age, original treatment 
site, original treatment modality, target volume, and type of mastectomy. The average age was 
54 y and the average volume of the planning target volume was 953.5 cm
3
.  
All patients were planned with both passively scattered and intensity modulated proton 
therapy techniques (Eclipse version 11). All patients were planned to the same prescription dose, 





Table 2.1 Anonymized patient cohort with a VMAT prescription dose of 50.4 Gy in 28 fractions 
for a left-sided unilateral mastectomy treatment site 
Research Index Age Treatment Site Planning Target Volume (cm
3
) 
CW-1 69 Left CW 1040.8 
CW-2 56 Left CW 778.9 
CW-3 27 Left CW 774.6 
CW-4 42 Left CW 1389.1 
CW-5 63 Left CW 1260.6 
CW-6 62 Left CW 781 
CW-7 46 Left CW 966.2 
CW-8 67 Left CW 637.1 
 
2.2 VMAT Treatment Planning 
VMAT treatment plans were created in Pinnacle
3
 v9.2 by certified radiation dosimetrists 
at Mary Bird Perkins Cancer Center following the current standard of care. Patients were treated 
on a linear accelerator (Elekta Ltd., Infinity, Crawley, UK), with two 6 MV photon arcs to a 
prescribed dose of 50.4 Gy in 28 fractions. The beam geometry consisted of a 0 degree couch 
angle and a 45 degree collimator angle. Due to the close proximity of the lungs, heart, and 
contralateral breast, PMRT is considered a complex case and thus two partial arcs were used for 
every patient. Each arc subtended an angle of 220˚ each with around 56 control points and 4-
degree final gantry spacing. The first arc was delivered counterclockwise with a starting angle of 
around 170-180˚ and ending at 310-320˚. The second arc was delivered clockwise with the start 
and stop angles opposite that of the first arc. The SmartArc optimization algorithm was used for 






Patients were treated in the supine position and the free breathing CT scans were obtained 
from the top of the head to the lower abdomen. Planning target volumes (PTV) were generated 
by the same radiation oncologist for all original VMAT plans and subsequently transferred to the 
proton TPS. As per ASCO guidelines, the PTV included the chest wall, and regional lymph 
nodes. The PTV also included a 1 cm tissue-equivalent bolus, which was placed on the surface of 
the treatment area prior to the patient’s initial CT scan and used during the course of treatment.  
Recording the dose within the bolus was not necessary for this study, and therefore the original 
PTV was altered to exclude the bolus for plan evaluation purposes and was closest to a clinical 
target volume. For accurate proton dose calculations a “Body” contour was created for each 
patient using an auto-contour tool called “search body” that outlined the entire patient anatomy 
and bolus (Rah et al., 2013). Any voxel outside of this body contour was excluded from any dose 
calculation.  
Figure 2.1 depicts the contours added or altered within the proton TPS. The green contour 
is the original physician drawn PTV used in VMAT dose calculations. The red contour is the 
new PTV without bolus structure that is identical to the original PTV drawn by the physician 
except it begins at the patient surface and not the bolus surface. The yellow contour is a 5 mm 
shell “skin” contour and is used to report the dose at the surface. The blue contour is a scanning 
target volume (STV) structure that was used for IMPT planning purposes, and is discussed in 
more detail below. 
To account for systematic range uncertainties within the proton treatment plans, proximal 
and distal margins for the PTV were added. For passively scattered proton treatment plans, all 




planning system and applied to the PTV without bolus, automatically. However, for active 
scanning proton plans the margins needed to be added manually to the PTV without bolus 
structure. These margins needed to be added to the PTV specifically because the treatment 
planning system for Intensity Modulated Proton Therapy does not incorporate the distal and 
proximal margins when added through the field properties. 
 
 
Figure 2.1 Planning target volumes for VMAT (green + red), PS (red), and IMPT (blue) along 
with a skin contour (yellow)  
 
Although the correct PTV concept for proton planning is beam specific, it is technically 
impossible to design a single volume from theoretical deduction in which to place spots that 
accounts for range uncertainties for multidirectional beams. Therefore, the PTV without bolus 
contour was expanded proximally by 1 mm, and 4 to 6 mm distally for all IMPT patient structure 
sets to create the scanning target volume (STV) used for IMPT planning (Figure 2.1 blue 
contour). These margin values are from the beam angle which necessitates the largest margin. 




were not added to the scanning target volume. These altered proton PTVs were then approved by 
the same radiation oncologist who created the original PTV prior to proton planning. 
Despite having different planning target volumes between modalities all plans were 
compared, except conformity, using the PTV without bolus structure (red contour) for simplicity 
and consistency. From here on out, dose reported to the PTV will refer to this evaluation PTV 
structure and not the volumes used for planning purposes. Table 2.2 summarizes the planning 
target volumes for each modality of proton therapy. 
Table 2.2 Planning target volume for proton plans 
Plan Planning Target Volume 
IMPT STV: Includes VMAT PTV without bolus volume with a 5 to 6 mm distal expansion and 
1 mm proximal expansion. Blue contour in Figure 2.1 
PS PsTV: Includes the original physician-drawn PTV but excludes the portion of the 
treatment volume that includes any part of the bolus. Red contour in Figure 2.1 
 
 The organs at risk (OARs) contours were created by either the physician or dosimetrist 
for the original VMAT plan. OARs that were contoured for the patients included the lungs (left 
and right), whole heart, contralateral breast, esophagus, trachea, and spinal cord. A new contour 
for the myocardium was created has a shell having an external contour 2 mm inside the external 
heart surface and a thickness varying from 1 cm to 2 cm, with the thickness on the left side being 
twice that on the right side (Zhang et al., 2013). 
 
2.4 Passive Scatter Proton Planning 
 Once all contours were complete a passive scatter plan was created similar to techniques 
used in previous proton PMRT studies (Ares et al., 2010; Macdonald et al., 2013a). The total 
prescribed dose was 50.4 Gy (1.8 Gy per fraction) relative biological effectiveness (RBE) (i.e. 




the PTV. The use of a generic RBE value of 1.1 is in accordance with the recommendations on 
dose prescription and reporting in International Commission on Radiation Units and 
Measurements Report 78 (ICRU, 2007). 
 One left-anterior oblique (LAO) field was used for six of the eight patients with beams 
angles ranging from 25˚-45˚. Angles were chosen to be as en-face as possible to the chest wall 
while allowing adequate margins within the snout (field) size. A snout size of 25x25 cm
2
 was the 
largest possible size we had PS commissioning data for and was used for all plans. Due to an 
inadequate dose distribution with a single LAO field, patient CW-2 used an anterior-posterior 
(AP) and LAO field combination with different beam weighting. Patient CW-4 was unable to 




Uncertainty margins were designed for each treatment field to ensure coverage of target 
volumes. Beam specific proximal (PM) and distal margins (DM) were calculated using a 
methodology similar to that used in previous proton planning studies (Macdonald et al., 2013a) 
and following the methods originally outlined by Moyers and Miller (2003) and Moyers et al. 
(2001). To approximate the proximal margin and distal margins the following equations were 
used: 
   [(            )                    (  )]                              ( ) 
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where the 3.5% accounts for CT HU conversion to stopping power inaccuracies, range is the 
nominal range defined by 90% dose on distal part of the Bragg peak or SOBP expressed in water 
equivalent depth.  Range uncertainty (RU) for passively scatter protons for this study was 3 mm 




system, and compensator density (Giebeler et al., 2013).  SOBP is the width of the spread out 
Bragg peak. Distal margins ranged from 0.6-0.7 cm for all patients and a proximal margin of 0.3 
cm was used for each patient.  
Once an angle was chosen, a brass block was added with a lateral uncertainty margin of 
0.8 to 1.2 cm. The minimum lateral margin needed was calculated using the following equation 
(Giebeler et al., 2013): 
                            (  )                                 ( ) 
where IM is the internal margin and for all plans was set to zero since this margin was already 
accounted for in the VMAT planning target volume. SM is the setup margin and again needed no 
further expansion from the PTV boundary. Therefore the only parameter needed to estimate the 
lateral margin needed was the beam energy and from that the 95%-50% penumbra. This 
minimum lateral margin was around 0.5 cm for a 160 MeV beam, however, this margin did not 
provide adequate lateral coverage of the PTV and thus an additional user defined margin of 3 to 
4 mm was added. This value was the smallest margin that provided adequate coverage. 
 Once the block margins were determined and set from the PTV without bolus structure a 
lucite compensator was added to the plan. Compensators conform the dose distribution to the 
distal end of the PTV. A smearing radius of 3 mm was used to account for any uncertainty in the 
alignment of the compensator to the patient and possible motion of the patient during the 
treatment. A border smoothing radius of 1 cm (default) was used for all patients. Border 
smoothing is used to avoid steep gradients of the compensator immediately below the block 
edge. Dose was then calculated for the patient and checked for adequate coverage both laterally 
and distally. If the dose distribution was not adequate, edits were made to the compensator and 




radiation oncologist who approved the original VMAT plans. Figure 2.2, shows the workflow for 
planning passively scattered proton therapy treatment plans. 
 
 
Figure 2.2 Passive scatter proton treatment planning workflow 
 
2.5 Intensity Modulated Proton Therapy Planning 
50.4 Gy (RBE) at 1.8 Gy (RBE) per fraction was prescribed to 100% of the PTV. Two 
fields were used for all patients: an anterior posterior field 0˚ and a left anterior oblique field 
with angles ranging from 30˚ to 45˚. Angles were chosen to get the best dose distribution within 
the supraclavicular region (AP beam) and chest wall region (LAO) and were consistent with 
methods used in a previous proton treatment study for breast cancer (Jimenez et al., 2013). A 
snout size of 40x30 cm
2
 was the largest possible size we had active scanning commissioning data 
for, and was used for all plans.  
The proximal margin and distal margins were calculated using the same methodology as 
passively scattered proton therapy (section 2.4). However, the range uncertainty value for IMPT 




many influential IMPT parameters and were required to get adequate lateral coverage of the 
target.  Lateral margins were set to the same value, 0.8 cm, as the block margins used in PS 
proton plans (Eq. 3). Unlike passive scatter proton plans, these uncertainty margins were not 
applied by the TPS due to limitations in the computer algorithm, and were thus applied manually 
to the planning target volume to create a scanning target volume. Figure 2.3 shows the treatment 
planning workflow for the IMPT technique. 
 
 
Figure 2.3 Intensity modulated proton therapy treatment planning workflow 
  
Intensity modulated proton planning in the proton TPS was enabled by selecting Multi 
Field Optimization. This allowed spot weights from both fields to be optimized at the same time 
to cover the target area and spare organs at risk. Two range shifters were added to the plan in 
order to achieve lower energies to cover the target volume. The energy range available for IMPT 
ranged from 70 to 250 MeV, however, our plans only required between 170 to 190 MeV. Prior to 
optimization a beam-line calculation was performed. This task located all possible spot positions 
from the range to the target plus margins, available energies, and definition of spot pattern. 
Optimization of the spot weights was done using Simultaneous Spot Optimization (SSO). SSO 
algorithm minimizes the objective function which consists of a basic part that accounts for the 




volume objectives. No repainting was chosen during the optimization process. Therefore a dose 
layer was only “painted” once.  
 Dose volume constraints for all fields were set up prior to dose optimization. Constraints 
were made for the PTV, STV, and OARs. Table 2.3 shows the starting constraints for all IMPT 
plans: 
Table 2.3 Preliminary IMPT dose volume objectives 




























Heart Upper 5% 5 Gy 50 
R Breast Upper 2% 5 Gy 50 
Cord Upper 5% 5 Gy 50 
Esophagus Upper 10% 15 Gy 50 
Airway Upper 10% 20 Gy 50 
 
2.6 Plan Acceptance Criteria 
VMAT, PS, and IMPT plans were all normalized so that the evaluation PTV received the 
same amount of dose for all modalities. This was accomplished by normalizing all plans to a 
mean dose of 50.4 Gy (RBE) within the evaluation PTV. After normalization, a proton plan was 
considered optimized when PTV D95% was at least 47.8 Gy (RBE), V107% was <2%, V20Gy (RBE) 
was <20% of total lung volume, and heart V22.5Gy (RBE) was <20%.  The dose constraint to the 
lung was chosen because it has been established as the threshold for risk of radiation 
pneumonitis in clinical practice. Similarly, the dose constraint to the heart correlates with 
increased rates of myocardial perfusion defects (Gagliardi et al., 2001). Target coverage was 




prescription dose, contrary to the International Commission on Radiation Units and 
Measurements (ICRU) recommendations of PTV D100% 95%, was due to the difficulties with 
VMAT acquiring ICRU coverage recommendation at the level of the skin; consequently, the 
PTV V95% > 95% is the more frequently used clinical value in breast radiotherapy (Ares et al., 
2010). Similarly, we allowed a PTV V107% of up to 2% value because this is more robust than 
evaluating a single point maximum dose. 
 
2.7 Dosimetric Plan Evaluation Metrics 
 The goal of aim one is to determine if the dose-volume treatment plan metrics between 
VMAT and proton therapies are statistically significantly different from each other for each 
patient. The goal of radiotherapy has always been to deliver 100% of the prescribed dose 
homogeneously to the entire target volume while simultaneously limiting dose to healthy tissues. 
Every radiotherapy treatment plan is subsequently optimized to meet this goal. Evaluation of 
treatment plans for the determination of best plan among different plans is accomplished by 
analysis of the dose volume histogram (DVH) as well as two-dimensional and three-dimensional 
spatial dose distributions. 
2.7.1 Planning Target Volume (PTV) 
The same evaluation planning target volume for all modalities was compared on the 
following dose-volume treatment plan metrics: 
Planning target volume (PTV): 
1. Dose volume histogram with clinical target volume shown as well 
2. Mean, maximum, and minimum dose to the PTV and standard deviation 
3. Dose that 95% of the PTV volume receives 
4. Volume that receives at least 95% of the prescription dose 
5. Volume that receives 107% or more of the prescription dose 
6. Dose Homogeneity Index (DHI) 




According to ICRU Report 68 the maximum and minimum dose to a region of interest 
are defined as the dose to 2% and 98% of each ROI respectively. This formalism was chosen to 
ignore small, clinically-insignificant hot or cold spots that may appear due to dose algorithm 
approximations. The dose to 98% of the PTV (D98%) will be used in conjunction with the dose to 
2% of the PTV to determine the level of dose homogeneity within the PTV using the following 
equation: 
    
         
   
                                                             ( ) 
where Dmax is the dose to 2% of the PTV volume and Dmin is the dose to 98% of the PTV volume 
and DRX is the prescribed dose (Wu et al., 2003). A value of zero would be the ideal 
homogeneity index. The PTV was also evaluated and compared on the conformity index (CI) or 
conformity number proposed by van’t Riet et al. (1997) using the following equation: 
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where TV is the target volume, RI is the reference isodose, and TVRI is the volume of the target 
that is covered by the reference isodose (Feuvret et al., 2006). 47.8 Gy (RBE) was used as the 
reference isodose. This conformity index takes into account irradiation of the target volume and 
irradiation of health tissues. The conformity index ranges from 0 to 1, where 1 is the ideal 
number. The PTV was also evaluated for acceptable coverage using V95% and V107% or the 
volume of the PTV that received at least 95% and no more than 107% of the prescribed dose. 
2.7.2 Organs at Risk (OARs) 
 The following parameters from the dose volume histograms were compared between 





Organs at Risk (OARs): 
1. Dose volume histogram for each organ (lungs, heart, contralateral breast, skin, 
esophagus, airway, spinal cord, and unspecified normal tissue) 
2. Mean and maximum dose to each OAR  and standard deviations 
3. Volume of lungs receiving  5, 10, and 20 Gy (RBE) or more 
4. Volume of heart receiving 5, 10, 22.5 and 30 Gy (RBE) or more 
5. Volume of contralateral breast receiving at least 5 Gy (RBE) or more 
 
The organs at risk that we are most interested in are the lungs, heart, contralateral breast, 
skin, esophagus, airway, spinal cord, and unspecified normal tissue. DVH values of interest for 
the total lung volume included the mean dose, V20Gy (RBE), V10Gy (RBE), V5Gy (RBE), and their 
respective standard deviations. The volume that receives at least 20 Gy (RBE) should be less 
than or equal to 20% of the total lung volume (V20Gy ≤ 20%) and was the metric we were most 
concerned with for the lungs since it is a well-established threshold for risk of radiation induced 
pneumonitis in clinical practice (Ares et al., 2010). The volume receiving at least 5 Gy (RBE) 
should be kept under 42% since this volume is associated with an increase in lung toxicity (Ares 
et al., 2010). The volume receiving at least 10 Gy (RBE) and the mean dose to each lung will 
also be compared.  
 The heart will be evaluated on the volumes receiving 5, 10, 22.5, and 30 Gy (RBE). 
Studies have shown that doses below 30 Gy (RBE) to the heart demonstrate no increase in 
cardiac mortality (Gagliardi et al., 1996; Gagliardi et al., 1998). Other studies quote that a dose 
of 22.5 Gy (RBE) has been shown to correlate with increased rates of reduced myocardial blood 
flow (Ares et al., 2010). The volume receiving 5 Gy (RBE) was used to evaluate the low dose 
contribution to the organ. 
 
2.8 Radiobiological Metric Comparison 
 Not only should radiation treatment plans be evaluated on physical quantities such as the 




of non-dosimetric factors such as normal tissue complication probability, tumor control 
probability, and secondary cancer complication probability for organs at risk with dose volume 
metrics increase the predictive power of complication incidence and provide a more robust 
method of comparing different radiotherapy treatment plans (Li et al., 2012).  
The goal of aim two was to determine if the following treatment plan metrics between 
VMAT and proton therapies were statistically significantly different from each other: normal 
tissue complication probability for the heart and lungs, tumor control probability, and the second 
cancer complication probability for the contralateral breast and lungs.  
Since the biological parameters used in the various dose-response models were derived 
from 2 Gy (RBE) fraction sizes and the current study delivered 1.8 Gy (RBE) fraction sizes, it 
was desired to correct the dose distributions for this fraction size discrepancy. Therefore, prior to 
the calculation of TCP, NTCP, and SCCP the linear quadratic model was used to correct each 
dose step in the corresponding differential DVH (dDVH) for fractionation with an α/β ratio of 3 
Gy (RBE) resulting in the normalized total dose distribution. 
2.8.1 Tumor Control Probability (TCP) 
Tumor control probability was calculated using the Webb and Brenner model (Brenner, 
1993; Webb and Nahum, 1993; Li et al., 2012), which accounts for repopulation. Since α, β, and 
n values for the chest wall are not available in literature, the chest wall was considered as a 
whole breast to retrieve said values. The model for the overall TCP is the product sum of 
probabilities of tumor control in each PTV dose bin i of the differential dose-volume histogram: 
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where N is the number of clonogens initially in the tumor and was found by the following 
equation: 
                                                                       ( ) 




 (Wigg, 2001), and V 
is the volume of the PTV. SF in Equation 7 is defined as the survival fraction as a function of 
dose, and is most commonly predicted with the linear-quadratic model for cell survival: 
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where α and β are constants representing the rate of lethal and sublethal cell damage 
respectively, and G is a constant that takes fractionation, and the half-time for sublethal damage 
repair into account where, G=1/x with x being the number of fractions. The parameter values 
suggested for TCP calculation are listed below in Table 2.4. 
 
Table 2.4 TCP parameter values 









2.8.2 Normal Tissue Complication Probability (NTCP)  
The Lyman-Kutcher-Burman (LKB) (Lyman, 1985; Kutcher and Burman, 1989; Mohan 
et al., 1992; Seppenwoolde et al., 2003) model was used to calculate the NTCP for the lungs. 
NTCP for the lungs was calculated with radiation pneumonitis grade two or higher as an 
endpoint: 
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Since an inhomogeneous dose was delivered to the lungs, the treatment plan dDVH values were 
reduced to an equivalent uniform dose using the following equation (Seppenwoolde et al., 2003). 
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where EUD is the dose, that if given uniformly to the entire volume, will lead to the same NTCP 
as the actual non-uniform dose distribution. Di is the dose per fraction to sub volume i, νi is the 
volume irradiated with dose Di in bin number i, and Vtot is the total lung volume. Di was 
corrected for fractionation using the linear-quadratic model with an α/β ratio of 3. TD50 is the 
uniform dose given to the entire organ that results in 50% complication risk, m is a measure of 
the slope of the dose-response curve, and n is the volume effect parameter. Table 2.5 gives the 
model parameter values used to calculate NTCP for the lungs. 
 
Table 2.5 Parameters to calculate NTCP (radiation pneumonitis) for the lungs  
Parameter Value 95% CI Source 
m 0.37 [0.28-0.56] 
(Seppenwoolde et al., 2003) n 0.99 [0.6-2.8] 
TD50 30.8 Gy (RBE) [23-46] 
 
 NTCP for the whole heart and myocardium was calculated using the relative seriality 
model (Kallman et al., 1992) which describes response of an organ with a mixture of serial- and 
parallel-arranged functional subunits (Li et al., 2012). NTCP is given by the following equation 
with cardiac mortality as the endpoint: 
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where vi is the fractional organ volume receiving a dose Di, n is the number of sub volumes in 
the dose volume histogram, s is the relative seriality of the organ which is defined as the ratio 
between the number of serial functional subunits to the total number of functional subunits. P(Di) 
is the probability of complication, and is defined by the following equation: 
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where γ is the maximum relative slope of the dose-response curve describing excess cardiac 
mortality at 15 years, and D50 is the dose associated with 50% complication probability. Table 
2.6 gives the parameters used to calculate NTCP for the heart. 
 
Table 2.6 Parameters to calculate NTCP (cardiac mortality) for the whole heart and myocardium  
Structure Parameter Value 68% CI Source 
Whole Heart 
D50 52.3 Gy -3.3, +4.7 
(Gagliardi et al., 2001) 
γ 1.28 -0.24, +0.36 
s 1 -0.27 
Myocardium 
D50 52.2 Gy -3.4, +4.7 
γ 1.25 -0.24, +0.37 
s 0.87 -0.24 
 
2.8.3 Second Cancer Complication Probability (SCCP) 
 Second cancer complication probability was calculated for the contralateral breast and 
lung using the Schneider model (Schneider et al., 2005):  
                                                                                                       (  ) 
where Inorg is the organ specific absolute cancer incidence rate in percent per gray (RBE). These 
values represent lifetime risk, and assume a residual life expectancy of 50 years. Therefore, any 
age related effect of radiation-induced breast cancer was ignored in this study. Inorg for the breast 
was estimated using atomic bomb survivor data and applies to whole-body irradiation. OEDorg is 




dose distribution, which if distributed evenly throughout the organ, causes the same radiation-
induced cancer incidence (Schneider et al., 2005).  OED was calculated using three different 
dose-response models: linear, linear-exponential, and linear-plateau based on the differential 
DVHs (Abo-Madyan et al., 2014)  
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where vi is the volume receiving dose Di and the summation runs over all voxels of organ T with 
volume VT. The parameters α and δ are the organ specific model parameters for their respective 
dose-response models. Parameters that were used to calculate SCCP are listed in Table 2.7. 
 





) Inorg (% / Gy) Source 
Breast 0.085 0.139 0.78 [0.6-1.0] 
(Schneider and Kaser-Hotz, 
2005b; Abo-Madyan et al., 
2014) 
Lungs 0.085 0.15 1.68 [1.1-2.3] 
(Schneider and Kaser-Hotz, 
2005b, a) 
  
2.9 Uncertainty Analysis 
Many uncertainties are associated with treatment planning with both photon and proton 
treatment planning modalities. Uncertainties analyzed within this work included the impact of 
isocenter shifts, proton range uncertainty on dose distribution and predicted risks, and sensitivity 




using the range uncertainty dose calculation tool within the proton TPS for a representative 
patient (CW-3).  
The two factors manipulated within the treatment planning range uncertainty tool were 
positional uncertainty and HU to relative linear stopping power (RLSP) calibration curve error. 
Positional uncertainty was simulated by an isocenter shift of 1 cm in all directions for one patient 
for all modalities (Wang et al., 2013). In the proton treatment planning system, the default 
coordinate system is defined as follows and for simplicity is referenced to a patient head first 
supine: the +X direction is to the patient’s left, +Y is posterior, and +Z is superior.  
 The HU to relative stopping power calibration curve was changed by ±3.5% and ±10% 
(Lomax et al., 2001; Wang et al., 2013) simulating a large systematic over- or under-shoot 
calibration error for the proton modalities. A positive percentage change indicated the proton 
stopping power value increased and the range became shorter compared to the range of the 
nominal plan. Conversely, a negative percentage change simulated a decrease in stopping power 
value and the range moved further from the source. This percentage was relative to the HU value 
in the calibration curve, therefore as the values on the curve increased, the correction also 
increased. Range uncertainty DVH data cannot be exported from the TPS. However, it was 
possible to simulate the isocenter shift and export that DVH data. The data from the calibration 
curve error was manually extracted from the TPS generated range uncertainty DVH at 0.5 Gy 
(RBE) intervals and then converted to a differential DVH for predicted risk calculations. New 
NTCP and SCCP values were generated for the isocenter shifts and calibration curve errors data. 
The sensitivity of the NTCP and SCCP models was analyzed using the nominal dose 
distributions. The sensitivity analysis for NTCP was accomplished by varying the model 




confidence interval. NTCP values were calculated for each patient for each parameter by taking 
all other parameters as a constant except for the parameter being varied within its 95% 
confidence interval. Then the average NTCP values for each set of parameters were calculated. 
In the case of lung NTCP, the parameters varied were the slope of the dose-response curve (m), 
D50, and the volume effect parameter (n). NTCP using the relative-seriality model varied the 
following parameters: the normalized dose response curve slope parameter (γ), D50, and the 
relative seriality parameter s. The parameter s describes the relative seriality of the organ and is 
defined as the ratio of the number of serial subunits to all subunits. According to this 
interpretation the s value should be between 0 and 1. However, an s value greater than 1 was 
allowed for this sensitivity analysis. 
 Sensitivity analysis of SCCP consisted of comparing the second cancer risk between 
three different dose-response models: linear, linear-exponential, and linear-plateau. The organ 
equivalent dose used in the calculation of SCCP was calculated using these models for the lungs 
and contralateral breast. At low doses (D < 2 Gy RBE) OED is the average organ dose because 
for low doses the risks are proportional to dose or the linear model. However, for doses higher 
than 2 Gy (RBE), radiation induced cancer incidence rates are not necessarily a linear function of 
dose. Therefore, comparing the results for the different risk models allows estimating the 
magnitude of the effect of the unknown shape of the dose-response curve.  
 Since there are large uncertainties associated with the dose-response models used, the 
ratios of NTCP (RNTCP) and SCCP (RSCCP) from the nominal proton PMRT and photon 
PMRT plans were also compared. To compare the risk values for NTCP we defined the ratio as: 
RNTCP= NTCPps or IMPT/NTCPVMAT. To compare the risk values for SCCP we defined the ratio 




Chapter 3 Results 
3.1    Patient CW-3 
 Minimal differences were observed between patients with regards to the dosimetric and 
radiobiological findings. For this reason, only one representative patient is presented here; 
meaning this patient had the most, not all, metrics closest to the mean of the sample population. 
Patient CW-3 was a 27 year old woman diagnosed with invasive ductal carcinoma of the upper-
outer quadrant of the left breast. After receiving a modified radical mastectomy the patient 
underwent post-mastectomy radiotherapy of the CW and regional lymph nodes using VMAT at 
Mary Bird Perkins Cancer Center. Results for the patient will be presented in the following 
fashion: 
1. Isodose distribution comparison 
2. DVH Comparison 
3. Dosimetric and radiobiological results for planning target volume 
4. Dosimetric and radiobiological results for lungs, heart, contralateral breast, and skin 
5. Impact of proton range uncertainties 
3.1.1 Isodose Distribution Comparison 
Isodose distributions for the VMAT, PS, and IMPT plans are shown for a transverse slice 
through VMAT beam isocenter (Figure 3.1). VMAT distributions are placed in the middle for 
ease of comparison between it and the proton plans. All treatment plans were normalized to the 
mean dose of the evaluation PTV, shown as the red contour. Color coding for the isodose 






Table 3.1 Color coding for isodose distributions  
Isodose Value Gy or Gy (RBE) Color 
55.0  Yellow 
52.9  Green 
50.4  Blue 
47.9  Cyan 
35.0  Orange 
25.0  Magenta 
15.0  Dark Green 
5.0 Red 
 
All techniques met the required PTV coverage, with 95% of the PTV receiving more than 
95% of the prescribed dose (47.9 Gy or Gy RBE), and the volume receiving 107% or more of the 
prescription dose (53.9 Gy or Gy RBE) was less than 2% of the PTV volume. All three 
techniques showed a high degree of conformity, with better conformity in the proton plans. The 
VMAT plan had higher maximum dose located medially than the proton plans. Both proton 
modalities significantly reduced the dose to the organs at risk, especially at the 5 Gy (RBE) level. 
The max dose to the target was reduced from VMAT to PS and IMPT, with IMPT having the 
lowest maximum dose, indicating a more homogeneous dose distribution. The dose to the 
contralateral breast was greatly reduced from VMAT to IMPT and PS, with PS having the lowest 
dose.  IMPT shows a low dose increase in the left posterior portion of the patient due to the AP 
beam used for dose coverage of the supraclavicular area that is not seen in the PS plans.  
Isodose distributions for VMAT, PS, and IMPT plans are shown for a transverse slice through a 
plane in the supraclavicular region of the PTV (Figure 3.2). Similar to the dose distributions 
through isocenter, all three modalities showed a high degree of dose homogeneity. However, 
there were several small spots receiving 52.9 Gy (RBE) in the anterior portion of the PTV in the 
PS plan due to the oblique entry angle of the beam. The 47.9 Gy (95%) isodose line extends 





Figure 3.1 Isodose distributions in transverse slice for PS, VMAT, and IMPT treatment plans. 





conformity for the proton plans. Also similar to the previous figure, the 5 and 15 Gy (RBE) 
isodose lines extended farther through the patient in the VMAT plan. 
3.1.2 DVH Comparison 
 
Figure 3.3 contains the cumulative dose volume histograms for VMAT and PS plans for 
this patient. Regions of interest included in the figure include the evaluation PTV, heart, lungs, 
and contralateral breast. Color coding for all dose volume histograms is listed in Table 3.2. 
Table 3.2 Color coding for regions of interest included in dose volume histograms for all 
treatment plans 
Region of Interest Color 
Contralateral Breast Green 
Heart Magenta 
Lungs Blue 
Evaluation PTV Red 
 
To describe DVHs a few terms must be defined. First the “shoulder” of the graph pertains 
to the PTV curve and describes the region where the curve begins to bend away from 100% of 
the PTV volume. Next the “falloff” of the graph also pertains to PTV curve and describes the 
vertical drop from prescription dose to zero dose. An ideal PTV curve would appear as having no 
shoulder and whose falloff would be a perfect vertical line from 100% volume to 0% volume at 
the prescription dose. For this patient, the VMAT and PS plans have nearly identical DVH 
curves for the PTV. Both curves for the PTV have a narrow shoulder and sharp distal falloff, 
representing a high degree of dose homogeneity. The major difference between these two plans 
becomes apparent when comparing the OARs.  
The VMAT plan had significantly higher volumes of the heart, lung, and contralateral 
breast receiving more dose than the PS plan. The volume of the lungs receiving 10 Gy (RBE) or 





Figure 3.2 Isodose distribution for PS, VMAT, and IMPT in the supraclavicular region as 







Figure 3.3 DVH comparing PS (dashed line) to VMAT (solid line) for patient CW-3 
 
of the lungs receiving above 40 Gy (RBE) was marginally higher for PS. The volume of the heart 
receiving 10 Gy (RBE) or less was about 20 times lower for the PS plan than VMAT. There was 
even more of a reduction seen, about 40 times, in the volume of the contralateral breast receiving 
10 Gy (RBE) or less for the PS plan versus VMAT. 
Figure 3.4 contains the cumulative dose volume histograms for VMAT and IMPT plans 
for this patient. Regions of interest included in the figure include the PTV (PTV-Bolus), heart, 
lungs, and contralateral breast. The PTV DVH for IMPT exhibits a narrower shoulder and 
steeper distal falloff than VMAT. This indicates IMPT had a better degree of conformity and 
homogeneity than VMAT. There was not as large as a reduction in dose to the OARs from 




the lungs receiving 10 Gy (RBE) or less was about 1.5 times as large for VMAT versus IMPT. 
The volume of the heart receiving 10 Gy (RBE) or less was about 4 times lower IMPT. There 
was even more of a reduction seen, about 20 times, in the volume of the contralateral breast 
receiving 10 Gy (RBE) or less for the IMPT plan versus VMAT.  
 
 
Figure 3.4 DVH comparing IMPT (dashed line) and VMAT (solid line) for patient CW-3 
 
3.1.3 PTV 
Results for patient CW-3 pertaining to the evaluation PTV are shown Table 3.3. No 
difference was seen between mean dose for all plans since normalization was set to the mean 
dose of the PTV. Maximum dose was defined as the dose to 2% of the PTV volume. Both proton 




the PTV volume. There was little difference between the minimum doses for VMAT and PS. 
There was however a more noticeable difference between the minimum doses for IMPT and 
VMAT, as was also shown in Figures 3.3 and 3.4. Dose coverage for 95% of the PTV volume 
exceeded the 47.9 Gy or Gy (RBE) dose requirements for all three plans. Better conformity was 
achieved with both proton plans, with IMPT having the highest degree of conformity.  This trend 
also applied to DHI, where IMPT had superior dose homogeneity. Both proton modalities 
achieved 100% tumor control and VMAT achieved 99.99% tumor control. 
 





















VMAT 50.4 52.6 47.3 48.3 96.7 0.0 0.60 0.11 99.99 
PS 50.4 52.2 47.9 48.5 98.1 0.1 0.80 0.09 100.00 
IMPT 50.4 51.5 49.1 49.5 99.8 0.0 0.85 0.05 100.00 
 
3.1.4  Lungs 
Table 3.4 summarizes the evaluation metrics used for the total lung volume in patient 
CW-3. Mean dose was lower by ~50% from VMAT to both proton modalities. Maximum dose 
was defined as the dose to 2% of total lung volume. Maximum doses were comparable between 
VMAT and IMPT modalities with IMPT having slightly lower dose. Maximum dose for PS was 
about 25% lower than VMAT. 43.7% of the lungs received a dose of 5 Gy (RBE) or higher 
whereas only 14.5% and 22% received this dose for PS and IMPT, respectively. The volume of 
lungs receiving 10 Gy (RBE) or more was again highest for VMAT with 25.5% and lowest for 
the PS plan with 12.3% and IMPT had 16.4%.  The same trend was seen for the volume of the 
lungs receiving 20 Gy (RBE) or more, however PS and IMPT were more comparable at this dose 
level with 9.4% and 9.8% respectively. VMAT had the highest mean dose and larger volumes 




with 1.9% and highest SCCP with 12.1%. NTCP for PS and IMPT were comparable with 0.9%. 
SCCP was lowest for PS with 6.2% and with IMPT SCCP was 6.4%. SCCP values reported here 
are calculated using the linear OED model (see section 2.8.3). 
 


















VMAT 9.4 43.7 46.7 25.5 14.2 1.93 12.06 
PS 4.3 31.3 14.5 12.3 9.4 0.89 6.24 
IMPT 4.8 39.5 22.0 16.4 9.8 0.90 6.37 
 
3.1.5 Heart 
Table 3.5 summarizes the evaluation metrics for the whole heart and myocardium for 
patient CW-3. VMAT had the highest mean dose with 8.0 Gy (RBE) to the whole heart with a 
maximum dose of 33.5 Gy (RBE). PS and IMPT had lower mean and maximum doses with PS 
having the most drastic reduction in dose. PS had a mean dose of 0.4 Gy (RBE) and a max dose 
of 5.8 Gy (RBE). IMPT had a mean dose of 1.6 Gy (RBE) and a maximum dose closer to VMAT 
of 24.8 Gy (RBE). Over 50% of the whole heart received 5 Gy (RBE) or more when using 
VMAT, but only 2.2% and 7.8% received this dose for PS and IMPT respectively. Differences in 
volume percentage receiving 30 Gy (RBE) or more became less drastic with 3.4%, 0.3% and 
1.4% of the whole heart for VMAT, PS, and IMPT respectively. VMAT had to highest NTCP for 
both the whole heart and myocardium, with 0.22% and 0.13% respectively. PS had the lowest 
NTCP at <0.01%. NTCP for IMPT was reduced from VMAT with 0.15% for the whole heart 
































VMAT 8.0 33.5 51.2 20.5 7.3 3.4 0.22 0.13 
PS 0.4 5.8 2.2 1.3 0.5 0.3 0.03 0.00 
IMPT 1.6 24.8 7.8 5.3 2.3 1.4 0.15 0.04 
 
3.1.6  Contralateral Breast  
Table 3.6 reports the doses, volumes, and second cancer complication probabilities for 
the contralateral breast for patient CW-3. There was a significant reduction in dose to the right 
breast using either proton modality compared to VMAT. The mean dose was 10.3 Gy (RBE) for 
VMAT, more than 10 times higher than both PS and IMPT. Maximum dose was 30.8 Gy (RBE) 
when using VMAT and only 0.3 Gy (RBE) for the PS treatment plan. When this patient was 
planned with IMPT a maximum dose of 10.9 Gy (RBE) was observed.  71.7% of the breast 
received 5 Gy (RBE) or more for the VMAT plan and this volume was drastically reduced to 
0.8% and 3.3% for PS and IMPT respectively. Consequently, the second cancer complication 
probability was highest for VMAT with 5.7%. SCCP for PS was 0.09% and 0.37% for IMPT. 
SCCP values reported here were calculated using the linear OED model (see section 2.8.3). 
 












VMAT 10.3 30.8 71.7 5.70 
PS 0.1 0.3 0.8 0.09 
IMPT 0.6 10.9 3.3 0.37 
 
3.1.7  Skin 
Table 3.7 reports the mean, maximum, and minimum doses to the skin for patient CW-3. 




of 50.4 Gy and 50.4 Gy (RBE) for proton plans. VMAT and PS plans had similar maximum 
doses of 52.5 Gy and 52.4 Gy (RBE) corresponding to 4% increase above prescription dose. The 
maximum dose reported for the IMPT plan was lower at 51.5 Gy (RBE) which corresponds to 
only a 2% increase above prescription.  Again, VMAT and PS had comparable minimum doses 
with 48.2 Gy and 48.1 Gy (RBE), respectively. This corresponds to a 4% decrease from 
prescription. IMPT had a more homogeneous dose distribution to the skin, indicated by the 
maximum dose previously mentioned and a minimum dose of 49.5 Gy (RBE), or about 98% of 
the prescription dose.  
 











VMAT 50.7 52.5 48.2 
PS 50.7 52.4 48.1 
IMPT 50.6 51.5 49.5 
 
3.1.8 Plan Robustness 
Dosimetric and radiobiological uncertainties associated with an isocenter shift and proton 
range were assessed for the representative patient, CW-3. A 1 cm isocenter shift in all directions 
was simulated in the proton TPS for both proton modalities and in the photon TPS for the 
VMAT plan. Cumulative and differential DVH data were exported. In the proton TPS, the 
default coordinate system was used and the X, Y, and Z directions are defined for a head-first 
supine patient as the following: +X refers to the patient’s left, +Y is posterior, and +Z is superior. 
In the photon TPS the coordinate system +X is to the patient’s left, +Y is anterior, and +Z is 





3.1.8.1 Positional Uncertainty for Patient CW-3 
Figures 3.5, 3.6, and 3.7 show the change in dose-volume statistics after a 1 cm isocenter 
shift was simulated for a VMAT treatment plan in all directions. The solid line in all following 
DVHs indicates the nominal plan, meaning no shift was applied to the calculated dose 
distribution. For each plan and shift the evaluation PTV, lungs, heart, and contralateral breast 
were plotted. Figure 3.5 shows the DVH for VMAT when a lateral shift to the left or right was 
made. The shift degraded the dose coverage within the PTV, with a shift to the right resulting in 
the lowest V95%. 
 
Figure 3.5 DVH showing PTV (red), lungs (blue), heart (magenta), and breast (green) after 1 cm 
isocenter shift laterally for VMAT 
 
 A shift to the patient’s right also caused the mean dose to increase in all organs, due to 
the organs shifting more into the beams eye view or treatment area. Despite the increase in OAR 
































volume receiving dose, no OARs were beyond their dose tolerances. We see a more pronounced 
cold dose shoulder for the PTV when the isocenter was shifted to the left. This shift also 
produced lower mean doses to the OARs. 
 
Figure 3.6 DVH showing PTV (red), lungs (blue), heart (magenta), and breast (green) after 1.0 
cm isocenter shift anterior or posterior for VMAT 
 
Figure 3.6 shows how the nominal VMAT dose distribution changed for a shift in the ±y-
direction. There was a significant dose shoulder for the PTV for an anterior shift, but the dose 
coverage, D95%, was higher for an anterior shift than posterior. A posterior shift greatly increased 
V5Gy (RBE), V10Gy (RBE), V22.5Gy (RBE), and V30Gy (RBE) to the heart which resulted in the highest risk 
of cardiac mortality at 1.22%.  
Figure 3.7 shows us that PTV coverage was diminished for both an inferior and superior 
shift for VMAT. An inferior shift caused V107% to increase from 0.0% to 1.6%, but a superior 
































shift resulted in poorer dose coverage within the PTV with D95% at only 43.7 Gy.  Mean dose and 
NTCP to the lungs was increased for an inferior shift but was decreased for a shift in the opposite 
direction. SCCP for the lungs remained around the same as the nominal risk estimate. Dose 
statistics for the contralateral breast and heart were very similar to the nominal plan.  
 
Figure 3.7 DVH showing PTV (red), lungs (blue), heart (magenta), and breast (green) after 1 cm 
isocenter shift superior or inferior for VMAT 
 
Table 3.8 lists of all dose-volume, NTCP, and SCCP values associated with the PTV, 
lungs, heart, and contralateral breast for a VMAT plan after a 1 cm isocenter shift was applied in 
each. For clarification on Dmax, Dmin, etc. please refer to section 2.7. NTCPmyo refers to the 
predicted risk for the myocardium and nominal refers to no shift or the original dose distribution. 
The criterion for an acceptable plan was D95%≥ 47.8 Gy of the PTV volume while keeping OARs 
































within their tolerance doses. All bolded values fail to meet the acceptance criterion. This VMAT 
plan failed to pass the PTV dose coverage criterion for a 1 cm in all directions; however no 
OARs received doses beyond their respective tolerance levels. Therefore this VMAT plan was 
not considered robust for an isocenter shift of 1 cm or greater.  
 
Table 3.8 Dose-volume and risk metrics for PTV, lungs, heart, and contralateral breast following 






Posterior Anterior Superior Inferior 
PTV 
Dmax 52.6 53.6 50.6 51.9 54.4 50.8 53.5 
Dmin 47.3 38.7 44.5 45.9 39.6 41.1 41.2 
D95% 48.3 43.1 45.9 46.4 43.9 43.7 46.1 
V95% 96.7 86.0 58.0 68.6 85.7 72.2 88.5 
V107% 0.0 0.9 0.0 0.3 3.5 0.0 1.6 
Lungs 
Dmean 9.4 8.0 10.7 11.0 7.8 8.5 10.2 
Dmax 43.7 39.7 45.5 45.3 39.4 41.2 45.4 
V5Gy 46.7 42.7 49.1 50.4 42.0 45.3 46.3 
V10Gy 25.5 22.0 28.6 30.5 20.3 23.3 27.3 
V20Gy 14.2 10.8 17.7 17.9 10.7 11.7 16.4 
NTCP 1.93 1.47 2.49 2.60 1.41 1.59 2.27 
SCCP* 12.06 9.96 14.10 14.46 9.66 10.59 13.35 
Heart 
Dmean 8.0 6.8 9.2 11.4 6.0 8.0 8.3 
Dmax 33.5 28.3 36.9 42.7 23.2 34.1 34.5 
V5Gy 51.2 45.1 54.8 61.1 40.2 49.8 52.1 
V10Gy 20.5 16.0 24.9 32.0 11.8 21.8 20.8 
V22.5Gy 7.3 4.4 10.5 16.5 2.2 7.4 8.3 
V30 Gy 3.4 1.4 5.7 10.9 0.6 3.6 4.1 
NTCP 0.22 0.06 0.40 1.22 0.02 0.21 0.25 
NTCPmyo 0.13 0.02 0.31 1.05 0.01 0.15 0.15 
R Breast 
Dmean 10.3 9.5 10.7 10.4 9.4 10.0 10.0 
Dmax 30.8 27.8 33.2 30.5 27.8 29.4 30.4 
V5Gy 71.7 70.9 71.0 79.3 63.7 70.6 71.5 
SCCP* 5.70 5.20 6.00 5.75 5.15 5.53 5.56 
*Linear OED dose- response model 





Figures 3.8, 3.9, and 3.10 show the DVHs for passively scattered proton therapy plans 
after an isocenter shift was applied. A lateral shift in either direction, as seen in Figure 3.8, 
decreased the dose coverage within the PTV by about 3%; however 95% of the PTV still 
received 95% of the prescription dose. An isocenter shift to the patient’s right increased the 
volume over the whole range of dose to the lungs, however decreased the volume in the heart 
and contralateral breast that received each dose level. A shift left had the opposite effect. Despite 
the increase of volume receiving dose, all critical organs were well within their tolerance doses. 
 
Figure 3.8 DVH showing PTV (red), lungs (blue), heart (magenta), and breast (green) after 1 cm 
isocenter shift laterally for PS.  
 
 A shift posteriorly or anteriorly did not affect the dose coverage, D95%, in the PTV. A 
posterior shift decreased the volume receiving 10 Gy (RBE) or more to the OARs aside from the 
































heart where the dose was increased from 1.3% to 2.1%.  An anterior shift increased the mean 
dose to the lungs as well as the contralateral breast.  
 
Figure 3.9 DVH showing PTV (red), lungs (blue), heart (magenta), and breast (green) after 1 cm 
isocenter shift anterior or posterior for PS 
 
 A shift inferior or superior for a passively scattered proton therapy plan had the greatest 
impact on dose coverage and dose to the OARs as seen in Figure 3.10. Shifting the isocenter 
point superiorly or a patient shift inferior causes V47.9 Gy (RBE) to decrease 3.4%.  A shift inferiorly 
decreased PTV coverage more with a 4.2% change from the nominal dose coverage of 98.1% of 
the PTV volume. Mean dose to the lungs increased when the point shifted inferior meaning the 
patient shifted superiorly causing more volume of the lung to be irradiated. All dose-volume 
metrics for the heart were decreased for an inferior isocenter shift.  

































Figure 3.10 DVH showing PTV (red), lungs (blue), heart (magenta), and breast (green) after 1 
cm isocenter shift superior or inferior for PS 
 
Table 3.9 summarizes all of the dose-volume and radiobiological metrics for the PTV, 
lungs, heart, and contralateral breast for a passively scattered proton therapy plan for patient 
CW-3 after a 1 cm isocenter shift was applied in each direction. For clarification on Dmax, Dmin, 
etc. please refer to section 2.7. NTCPmyo refers to the predicted risk for the myocardium and 
nominal refers to no shift or the original dose distribution. The criterion for an acceptable plan 
was D95%≥ 47.8 Gy (RBE) of the PTV volume while keeping OARs within their tolerance doses. 
A 1 cm shift inferiorly failed to meet the dose coverage for the PTV by 1 Gy (RBE), but the 
OARs were still within acceptable limits. Therefore, this PS plan was considered robust (meet 
most or all criteria) up to 1 cm shift. 
 
































Table 3.9 Dose-volume and risk metrics for PTV, lungs, heart, and contralateral breast following 






Posterior Anterior Superior Inferior 
PTV 
Dmax 52.2 52.6 52.6 47.7 47.7 52.9 52.9 
Dmin 47.9 44.8 44.5 52.3 52.3 38.9 37.1 
D95% 48.5 48 47.9 48.5 48.5 47.8 46.8 
V95% 98.1 95.4 95.1 97.5 97.4 94.8 94.0 
V107% 0.1 0.2 0.2 0.1 0.1 0.2 0.2 
Lungs 
Dmean 4.3 4.0 6.4 4.7 4.9 3.6 6.6 
Dmax 48.0 49.6 50.0 48.9 48.2 45.9 50.8 
V5Gy (RBE) 14.5 12.3 20.4 13.1 16.6 10.8 18.3 
V10Gy (RBE) 12.3 10.6 17.7 11.2 14.1 8.8 16.4 
V20Gy (RBE) 9.4 8.4 14.0 8.8 10.8 6.5 13.8 
NTCP 0.89 0.85 1.40 0.86 1.00 0.68 1.49 
SCCP* 6.24 5.89 9.51 5.96 7.08 4.41 9.97 
Heart 
Dmean 0.4 0.9 0.2 0.6 0.3 0.7 0.3 
Dmax 5.8 17.8 2.3 10.4 3.4 10.9 3.5 
V5Gy (RBE) 2.2 3.9 1.1 3.0 1.5 3.1 1.6 
V10Gy (RBE) 1.3 2.9 0.5 2.1 0.8 2.1 1.0 
V22.5Gy (RBE) 0.5 1.6 0.1 1.0 0.2 1.1 0.3 
V30 Gy (RBE) 0.3 1.2 0.0 0.6 0.1 0.7 0.2 
NTCP 0.03 0.24 0.00 0.10 0.01 0.12 0.01 
NTCPmyo 0.00 0.04 0.00 0.01 0.00 0.01 0.00 
R Breast 
Dmean 0.1 0.0 0.7 0.3 0.4 0.3 0.7 
Dmax 0.3 0.1 13.3 0.1 3.4 1.5 0.1 
V5Gy (RBE) 0.8 0.0 2.8 0.2 1.8 1.3 0.4 
SCCP* 0.09 0.03 0.48 0.04 0.24 0.17 0.06 
*Linear OED dose- response model 
BOLDED values fail to meet plan acceptance criteria 
 
Figure 3.11 shows the DVH after a 1 cm isocenter shift was applied in the lateral 
directions for an IMPT dose distribution on patient CW-3. A shift to the patient’s left decreased 
D95% from 49.5 Gy (RBE) to 47 Gy (RBE), which fails to meet the 47.9 Gy (RBE) plan 
acceptance criteria. This shift also caused Dmax to increase from 51.5 Gy (RBE) to 54.3 Gy 
(RBE) and V107% increased from 0% to 3%. Despite not having acceptable PTV dose coverage 




contralateral breast. An isocenter shift to the patient’s right by 1 cm caused an even greater 
decrease in D95%, 45.1 Gy (RBE), but had a lower Dmax to the PTV. This shift also caused an 
increase in mean dose to the lungs, and contralateral breast, but decreased the mean dose to the 
heart. A shift to the patient’s right increased the risk of radiation pneumonitis the most from 
0.9% to 1.31% and also had the highest SCCP risk.  
 
Figure 3.11 DVH showing PTV (red), lungs (blue), heart (magenta), and breast (green) after 1 
cm isocenter shift laterally for IMPT 
 
 A shift posteriorly or anteriorly in the IMPT plan decreased D95% from 49.5 Gy (RBE) to 
46.0 Gy (RBE) and 47.6 Gy (RBE) respectively as seen in Figure 3.12. However, the dose to 
20% of the lungs or greater was very similar to the nominal dose distribution.  Dmax for the PTV 
increased for both shifts and Dmin decreased which indicates less dose homogeneity and 
































conformity. A posterior shift increased the mean dose to the heart but decreased the mean dose to 
the lungs and contralateral breast.  
 
Figure 3.12 DVH showing PTV (red), lungs (blue), heart (magenta), and breast (green) after 1 
cm isocenter shift anterior or posterior for IMPT 
 
Figure 3.13 demonstrates how the nominal dose distribution for an IMPT plan changed 
for an inferior or superior isocenter shift of 1 cm. The PTV received similar dose coverage 
statistics for both z-shifts, however a shift inferior resulted in worse dose homogeneity. This shift 
did not cause much change from the nominal distribution for the heart and contralateral breast; 
however the mean dose to the lung increased. Due to the increased volume receiving dose in the 
lungs, the risk of radiation pneumonitis increased from 0.9% to 1.51%.  
 

































Figure 3.13 DVH showing PTV (red), lungs (blue), heart (magenta), and breast (green) after 1 
cm isocenter shift superior or inferior for IMPT 
 
 In summary, an isocenter shift of 1 cm in any direction (x,y,or z) for IMPT caused the 
dose coverage in the PTV to drop below 47.9 Gy (RBE) to 95% of the volume which was a 
criterion for plan acceptance. Despite poor dose coverage within the PTV, no OARs were out of 
their respective tolerance doses (see section 2.6). Table 3.10 lists all the dose-volume and 
radiobiological metrics for the PTV, lungs, heart, and contralateral breast following a 1 cm 
isocenter shift in all directions for patient CW-3 for an IMPT treatment plan. For clarification on 
Dmax, Dmin, etc. please refer to section 2.7. NTCPmyo refers to the predicted risk for the 
myocardium and nominal refers to no shift or the original dose distribution. 
 
































Table 3.10 Dose-volume and risk metrics for PTV, lungs, heart, and contralateral breast 






Posterior Anterior Superior Inferior 
PTV 
Dmax 51.5 54.3 52.7 54.2 54.5 52.3 52.2 
Dmin 49.1 45.3 43.1 45.1 46.7 39.8 33.7 
D95% 49.5 47.0 45.1 46.0 47.6 45.6 43.6 
V95% 99.8 91.7 78.7 80.9 93.3 91.6 91.0 
V107% 0.0 3.0 0.5 2.5 3.8 0.4 0.0 
Lungs 
Dmean 4.8 3.9 6.7 4.7 5.2 4.0 6.5 
Dmax 39.5 41.2 44.1 40.8 39.0 38.0 47.4 
V5Gy (RBE) 22.0 17.0 27.8 20.7 24.7 18.4 25.2 
V10Gy (RBE) 16.4 12.6 22.0 15.6 17.9 13.0 20.5 
V20Gy (RBE) 9.8 7.7 14.5 9.8 10.2 7.3 14.1 
NTCP 0.90 0.77 1.31 0.89 0.96 0.76 1.31 
SCCP* 6.37 5.29 9.05 6.26 6.80 5.21 9.06 
Heart 
Dmean 1.6 2.2 1.6 2.0 1.2 1.7 1.4 
Dmax 24.9 31.4 16.7 29.0 20.0 27.4 22.0 
V5Gy (RBE) 7.8 10.1 5.8 9.9 6.2 7.8 7.4 
V10Gy (RBE) 5.3 7.3 3.5 7.0 4.1 5.4 4.8 
V22.5Gy (RBE) 2.3 3.6 1.3 3.2 1.7 2.7 1.9 
V30 Gy (RBE) 1.4 2.2 0.6 1.8 0.9 1.7 1.0 
NTCP 0.15 0.28 0.06 0.20 0.07 0.23 0.09 
NTCP myo 0.04 0.10 0.01 0.07 0.01 0.07 0.02 
R Breast 
Dmean 0.6 0.2 1.5 0.4 0.9 0.8 0.5 
Dmax 10.9 2.7 29.5 7.5 15.8 14.5 7.7 
V5Gy (RBE) 3.3 1.2 6.1 2.6 4.7 4.1 2.6 
SCCP* 0.37 0.11 0.97 0.26 0.55 0.48 0.29 
*Linear OED dose response model 
BOLDED values fail to meet plan acceptance criteria 
 
3.1.8.2 Proton Range Uncertainty for Patient CW-3 
Using the Eclipse range uncertainty tool a ±3.5% and ±10% HU to relative stopping 
power calibration curve error was introduced to the nominal proton plan for IMPT and PS for the 
representative patient (CW-3). Figures 3.14 and 3.15 show the changes in the nominal DVH after 




Figure 3.14 Range uncertainty DVH for patient CW-3 for PTV (red), lungs (blue), heart 
(magenta), and contralateral breast (green) for a ±3.5% simulated HU to relative stopping power 





Figure 3.15 Range uncertainty DVH for patient CW-3 for PTV (red), lungs (blue), heart 
(magenta), and contralateral breast (green) for a ±3.5% simulated HU to relative stopping power 





A negative 3.5% relative linear stopping power (RLSP) error increased the mean dose to 
the lungs and heart for both IMPT and PS due to the increase in range. A positive 3.5% had the 
opposite effect because of the decrease in range. This decrease in range caused the dose coverage 
in the PTV for the IMPT plan to slightly decrease in the 48 to 50 Gy (RBE) shoulder region. 
Despite the small change, the IMPT plan with a +3.5% RLSP error was still able to meet all plan 
acceptance criteria and therefore was deemed a robust plan. The PTV DVH for the PS plan did 
not change and was also determined to be a robust plan.  
 A ±10% RLSP error was also applied to the same IMPT and PS proton plans and 
provided a worst-case scenario. Figures 3.16 and 3.17 display these range uncertainty DVHs for 
IMPT and PS proton plans, respectively. A -10% RLSP error caused a large systematic increase 
in the DVH statistics for the lungs and heart for both proton modalities. However, a +10% error 
decreased the mean dose to those organs. Neither a positive or negative error appeared to alter 
the nominal dose distribution for the contralateral breast. The dose to the PTV for IMPT 
increased for a -10% error starting at 80% of the volume and lower, with the largest increase in 
dose occurring to only 5% of the PTV. When a +10% error was applied, the PTV DVH was 
impacted the most seen by the decrease in D95%. The IMPT plan still met the plan acceptance 
PTV criteria of D95% > 47.9 Gy (RBE) and was considered robust for up to a ±10% RLSP error. 
 Similarly, the passively scattered proton plan was also deemed robust, since all dose-
volume acceptance criteria were met. The same DVH trends for the OARs from IMPT were seen 
for the PS proton plan. However, the PS range uncertainty DVH was different from the IMPT 
plan with regards to the PTV coverage. The nominal PTV dose-volume statistics for PS did not 




Figure 3.16 Range uncertainty DVH for patient CW-3 for PTV (red), lungs (blue), heart 
(magenta), and contralateral breast (green) for a ±10% simulated HU to relative stopping power 





Figure 3.17 Range uncertainty DVH for patient CW-3 for PTV (red), lungs (blue), heart 
(magenta), and contralateral breast (green) for a ±10% simulated HU to relative stopping power 





 Since a 3.5% calibration curve error did not change the IMPT and PS proton dose 
distributions as much as the ±10% RSLP error did, it was decided to only recalculate the normal 
tissue complication risks for the lung, heart, myocardium and risk of second cancer for the lung 
and contralateral breast for the ±10% RSLP error DVHs. Table 3.11 summarizes these range 
uncertainty risks for both proton modalities.  
Table 3.11 NTCP (%) and SCCP (%) for the lungs, heart, and contralateral breast for patient 
CW-3 for a simulated 10% HU to relative stopping power calibration curve error introduced to 














Nominal (0%) 0.90 6.37 0.15 0.04 0.37 
-10% 1.74 10.91 0.74 0.41 0.39 
10% 0.60 3.73 0.01 0.00 0.36 
PS 
Nominal (0%) 0.89 6.24 0.03 0.00 0.09 
-10% 2.09 12.25 0.53 0.23 0.09 
10% 0.48 2.31 0.00 0.00 0.09 
VMAT Nominal (0%) 1.93 12.06 0.22 0.13 5.7 
 
There was a systematic increase in all risks when a -10% error was assumed for both the 
IMPT and PS proton plans. SCCP (linear) for the lung for both IMPT and PS increased the most 
for a 10% undershoot in HU to stopping power conversion. This change from the nominal risk 
was 4.54% for IMPT and 6.01% for PS plans. NTCP for the lungs and heart and also SCCP for 
the lungs calculated for a -10% RLSP error in the PS plan were predicted to be slightly higher 
than values associated with VMAT plan for this same patient. Also, NTCP for the heart 
calculated for a -10% RLSP error in the IMPT plan were predicted to be higher than VMAT. 
SCCP for the breast was still substantially lower than VMAT despite the introduced RLSP error. 




was therefore concluded that IMPT and PS proton plans were robust for up to a 10% over- or 
undershoot in stopping power conversion. 
3.2 Overview of Results for the Sample of Patients 
Results for patients in this sample are presented in the following sections. Patient CW-4 
had no results for a PS plan because the PTV was larger than the maximum snout size of 25x25 
cm
2
. Despite having one less patient in the PS cohort, statistical power of >80% for the results 
was obtained. Mean values (± 1σ) are given for each evaluation metric. Statistical significance 
was determined for each comparison (VMAT vs. PS and VMAT vs. IMPT) using a paired, two-
tailed Student’s t-test and Wilcoxon signed-rank test with a significance level of p = 0.05. 
3.2.1 PTV 
Tables 3.12 and 3.13 list the dose volume and radiobiological metrics results used to 
evaluate the PTV for VMAT, PS, and IMPT radiotherapy treatment plans. PS and IMPT showed 
a statistically significant advantage in dose coverage with a mean dose to 95% of the PTV of 
48.6±0.4 Gy (RBE) (p = 0.043) for PS and 49.4±0.4 Gy (RBE) (p = 0.001) for IMPT compared 
to VMAT.  The dose to 95% of the PTV for VMAT was lower, 47.8±0.6 Gy. PS and IMPT 
achieved significantly better (p = 0.016 and p = 0.001, respectively) dose conformity than 
VMAT. Mean conformity values for VMAT, PS and IMPT were 0.72±0.08, 0.81±0.03 and 
0.86±0.02, respectively. PS and IMPT also had significantly better dose homogeneity over 
VMAT. However, there were no statistically significant differences found between modalities in 
terms of TCP. There was also no statistical difference between VMAT and PS in maximum dose 
to the PTV. The mean dose value for VMAT was 52.7±0.4 Gy and the mean dose value for PS 
was 52.3±0.3 Gy (RBE). However, there was a statistical difference between VMAT and IMPT 




value of 51.7±0.3 Gy (RBE). Mean values for the minimum dose (D98%) for both PS and IMPT 
were found to be statistically different from the corresponding mean value for VMAT. The 
average minimum dose for VMAT was 46.4±0.7 Gy, 48.0±0.6 Gy (RBE) (p = 0.009) for PS, and 
48.7±0.4 Gy (RBE) (p < 0.001) for IMPT.  
3.2.2 Lungs 
Results for the lungs for each patient are listed in Tables 3.14 and 3.15.  ̅     in the 
lungs was statistically significantly lower for both PS and IMPT when compared to VMAT (p < 
0.001).  ̅     for PS was 4.0±1.9 Gy (RBE), 4.2±1.2 Gy (RBE) for IMPT, and 9.8±0.7 Gy for 
VMAT. No statistically significant difference was detected between PS and VMAT for the 
patient averaged maximum dose; however  ̅    for IMPT was statistically significantly lower 
than that for VMAT (p < 0.001). On average more than half the lung volume, 53.2%±10.6%, 
received 5 Gy (RBE) or more with VMAT compared to only 13.1%±4.6% with PS and 
19.0%±3.9% with IMPT, with both proton modalities producing statistically significant 
reductions in  ̅    (   ) (p < 0.001). The mean volume of the lungs receiving 10 Gy (RBE) or 
more was statistically significantly lower for both proton modalities with  ̅     (   ) values of 
11.2%±4.4% for PS (p < 0.001), 14.4%±3.5% with IMPT (p = 0.001) and 28.4%±4.6% with 
VMAT. There was also a statistically significant reduction in V20Gy (RBE) for both proton 
modalities with comparable average V20Gy (RBE) values of 8.7%±4.1% (p = 0.002) with PS and 
8.7%±3.0% (p < 0.001) with IMPT compared to VMAT, which had an average V20Gy of 
14.2%±1.6%. Consequently,     ̅̅ ̅̅ ̅̅ ̅̅  and     ̅̅ ̅̅ ̅̅ ̅ were statistically significantly lower for PS and 
IMPT compared to VMAT (p < 0.001).     ̅̅ ̅̅ ̅̅ ̅̅  was reduced from 2.0%±0.2% in VMAT to 
0.9%±0.4% in PS and 0.8%±0.2% in IMPT.     ̅̅ ̅̅ ̅̅ ̅ values were reduced from 12.5%±0.9% in 





Tables 3.16 and 3.17 list the dose volume and radiobiological metrics used to evaluate the 
heart for each patient. The first metric compared between the modalities was the patient averaged 
mean dose ( ̅    ) to the whole heart.  ̅     values were statistically significantly lower (p < 
0.001) for PS (0.4±0.3 Gy (RBE)) and IMPT (0.5±0.5 Gy (RBE)) compared to VMAT (12.4±2.0 
Gy).   ̅    values were also statistically significantly lower for both proton modalities (p < 
0.001) compared to VMAT with  ̅    values of 5.9±6.0 Gy (RBE), 8.5±7.7 Gy (RBE), and 
39.2±5.3Gy for PS, IMPT, and VMAT, respectively. The volume receiving 5 Gy (RBE) or more 
was statistically significantly reduced from 88.0±16% with VMAT to 2.0±1.2% and 3.1±2.3% 
using PS and IMPT (p < 0.001), respectively. Similarly, the patient averaged volume receiving 
10 Gy (RBE) or more was statistically significantly reduced using both proton modalities 
compared to that of VMAT (p < 0.001) with  ̅    (   ) values of 1.3%±0.9%, 1.8%±1.6%, and 
47.2%±15.1% for PS, IMPT, and VMAT, respectively.  ̅      (   )  and  ̅    (   )  were also 
statistically significantly lower (p ≤ 0.001)  for both proton modalities compared to VMAT; with 
<1% of the whole heart volume receiving these doses using PS and IMPT compared to 
12.1%±3.2% ( ̅      ) and 7%±3.1% ( ̅    ) using VMAT. Subsequently, the patient averaged 
predicted risk of cardiac mortality (    ̅̅ ̅̅ ̅̅ ̅̅ ) for the whole heart was statistically significantly 
lower for PS (p < 0.017) and IMPT (p = 0.014) when compared to VMAT.  The mean risk of 
cardiac mortality was also statistically significantly lower for the myocardium for PS (p = 0.019) 
and IMPT (p = 0.020) compared to VMAT.     ̅̅ ̅̅ ̅̅ ̅̅  for the whole heart and myocardium were 




Table 3.12 Selected PTV evaluation metrics for VMAT, PS, and IMPT plans. Abbreviations: 
Dmax = maximum dose; Dmin = minimum dose; D95% = dose that 95% of the volume receives; PS 
p-value = VMAT vs. PS; IMPT p-value = VMAT vs. IMPT.  
Patient 
Dmax [Gy (RBE)] Dmin [Gy (RBE)] D95% [Gy (RBE)] V95% [%] 
VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT 
1 53.3 52.2 51.4 45.6 48.0 49.3 46.9 48.4 49.9 90.8 98.3 99.9 
2 52.4 52.9 52.2 47.1 46.8 48.1 48.5 47.8 49.2 96.9 94.9 99.1 
3 52.6 52.2 51.5 47.3 47.9 49.1 48.3 48.5 49.5 96.7 98.1 99.8 
4 52.8 - 51.5 46.3 - 48.6 47.5 - 49.5 93.2 - 99.4 
5 52.6 52.4 51.6 45.7 47.7 48.6 47.6 48.6 49.7 94.1 97.7 99.7 
6 52.8 52.1 52.0 45.9 48.5 48.3 47.7 49.0 49.5 94.3 99.1 99.4 
7 52.1 52.2 51.4 47.3 48.7 49.1 48.4 49.1 49.8 96.7 99.7 100.0 
8 52.8 51.9 51.6 45.8 48.4 48.6 47.3 48.9 49.3 93.0 99.1 99.6 
Mean 52.7 52.3 51.7 46.4 48.0 48.7 47.8 48.6 49.4 94.5 98.1 99.6 
σ 0.3 0.3 0.3 0.7 0.6 0.4 0.6 0.4 0.4 2.2 1.6 .0.3 
p-value 
PS IMPT* PS* IMPT* PS** IMPT* PS* IMPT* 
0.123 0.001 0.009 <0.001 0.043 <0.001 0.026 <0.001 
* Statistical significance detected using both Student’s t-test and Wilcoxon signed-rank test  
** Statistical significance only found using Student’s t-test  
 
Table 3.13 Selected PTV evaluation metrics for VMAT, PS, and IMPT plans. Abbreviations: 
V107% = volume that receives at least 107% of the prescription dose; CI = conformity index; DHI 
= dose homogeneity index; TCP = tumor control probability. 
Patient 
V107% [%] CI DHI TCP 
VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT 
1 0.8 0.0 0.0 0.79 0.84 0.89 0.15 0.09 0.04 97.5% 100.0% 100.0% 
2 0.0 0.5 0.0 0.79 0.82 0.85 0.11 0.12 0.08 92.7% 99.3% 99.7% 
3 0.0 0.1 0.0 0.60 0.80 0.85 0.11 0.09 0.05 100.0% 100.0% 100.0% 
4 0.1 - 0.0 0.61 - 0.87 0.15 - 0.06 100.0% - 100.0% 
5 0.0 0.0 0.0 0.72 0.81 0.88 0.14 0.09 0.06 100.0% 100.0% 100.0% 
6 0.1 0.0 0.0 0.72 0.76 0.83 0.14 0.07 0.07 100.0% 100.0% 100.0% 
7 0.2 0.0 0.0 0.80 0.85 0.89 0.10 0.07 0.05 100.0% 100.0% 100.0% 
8 0.1 0.0 0.0 0.74 0.78 0.85 0.13 0.07 0.06 100.0% 100.0% 100.0% 
Mean 0.2 0.1 0.0 0.72 0.81 0.86 0.13 0.09 0.06 98.8% 99.9% 100.0% 
σ 0.3 0.2 0.0 0.08 0.03 0.02 0.02 0.02 0.01 2.6% 0.2% 0.1% 
p-value 
PS IMPT PS* IMPT* PS* IMPT* PS IMPT 
0.628 0.134 0.016 0.001 0.013 <0.001 0.220 0.220 




Table 3.14 Selected lung evaluation metrics for VMAT, PS, and IMPT plans. Abbreviations: 
Dmean = mean lung dose; Dmax = maximum dose; V5Gy (RBE) = volume that receives at least 5 Gy 
(RBE); PS p-value = VMAT vs. PS; IMPT p-value = VMAT vs. IMPT.   
Patient 
Dmean [Gy (RBE)] Dmax [Gy (RBE)] V5Gy (RBE) [%] 
VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT 
1 9.9 2.4 3.1 37.3 40.9 30.7 65.2 8.9 16.6 
2 8.7 1.8 3.6 43.2 31.3 35.6 40.5 7.5 17.7 
3 9.4 4.3 4.8 43.7 48.0 39.5 46.7 14.5 22.0 
4 10.4 - 2.4 38.7 - 31 64.5 - 11.6 
5 9.5 5.4 5.0 47.2 49.4 43.4 43.9 16.1 20.1 
6 10.4 7.1 6.2 46.4 50.2 45.3 45.5 19.7 24.1 
7 9.4 2.7 3.6 43.1 44.6 34.6 53.3 9.4 17.9 
8 10.9 4.7 4.8 43.4 47.9 39.1 66.1 15.9 22.0 
Mean 9.8 4.0 4.2 42.9 44.6 37.4 53.2 13.1 19.0 
σ 0.7 1.9 1.2 3.4 6.7 5.4 10.6 4.6 3.9 
p-value 
PS* IMPT* PS IMPT* PS* IMPT* 
<0.001 <0.001 0.625 <0.001 <0.001 <0.001 
* Statistical significance detected using both Student’s t-test and Wilcoxon signed-rank test 
 
Table 3.15 Selected lung evaluation metrics for VMAT, PS, and IMPT plans. Abbreviations: 
V10Gy (RBE) = volume that receives at least 10 Gy (RBE); V20Gy (RBE) = volume that receives at least 
20 Gy (RBE); NTCP = normal tissue complication probability; SCCP = second cancer 
complication probability; PS p-value = VMAT vs. PS; IMPT p-value = VMAT vs. IMPT.  
Patient 
V10Gy (RBE) [%] V20Gy (RBE) [%] NTCP [%] SCCP [%] 
VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT 
1 31.9 7.2 11.5 12.3 5.1 5.8 1.94 0.59 0.64 12.14 3.40 3.99 
2 22.7 5.7 13.1 14.2 3.6 7.3 1.74 0.50 0.72 11.24 2.42 4.77 
3 25.5 12.3 16.4 14.2 9.4 9.8 1.93 0.89 0.90 12.06 6.24 6.37 
4 36.0 - 8.7 13.3 - 4.8 2.10 - 0.56 12.74 - 3.08 
5 24.0 14.2 16.1 14.4 11.7 11.2 2.03 1.14 0.98 12.46 8.02 6.97 
6 28.6 17.8 19.7 17.3 15.2 13.8 2.37 1.64 1.24 13.69 10.69 8.65 
7 26.3 7.8 12.8 12.7 5.7 6.9 1.88 0.63 0.71 11.88 3.88 4.67 
8 32.4 13.5 16.7 15.1 10.3 10.1 2.40 0.96 0.90 13.80 6.78 6.37 
Mean 28.4 11.2 14.4 14.2 8.7 8.7 2.05 0.91 0.83 12.50 5.92 5.61 
σ 4.6 4.4 3.5 1.6 4.1 3.0 0.23 0.39 0.22 0.88 2.91 1.81 
p-value 
PS* IMPT* PS* IMPT* PS* IMPT* PS* IMPT* 
<0.001 0.001 0.002 <0.001 <0.001 <0.001 <0.001 <0.001 





Table 3.16 Selected heart evaluation metrics for VMAT, PS, and IMPT plans. Abbreviations: 
Dmean = mean dose; Dmax = maximum dose; V5Gy (RBE) = volume that receives at least 5 Gy 
(RBE); V10Gy (RBE) = volume that receives at least 10 Gy (RBE).  
Patient 
Dmean [Gy (RBE)] Dmax [Gy (RBE)] V5Gy (RBE) [%] V10Gy (RBE) [%] 
VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT 
1 13.0 0.1 0.5 30.8 0.4 7.4 98.0 0.6 2.8 62.0 0.3 1.4 
2 12.4 0.3 0.4 38.2 3.4 5.4 93.9 1.7 2.1 50.8 1.1 1.1 
3 8.0 0.4 1.6 33.5 5.8 24.8 51.2 2.2 7.8 20.5 1.3 5.3 
4 12.7 - 0.1 38.0 - 0.7 99.7 - 0.7 58.0 - 0.3 
5 11.3 0.3 0.2 45.3 3.5 2.2 79.9 1.6 1.2 27.3 0.9 0.6 
6 14.7 1.0 0.8 45.9 18.6 14.1 91.8 4.4 4.6 57.0 3.2 2.9 
7 13.1 0.4 0.4 39.4 6.9 5.4 95.0 2.5 2.1 48.2 1.5 1.1 
8 13.5 0.2 0.5 42.3 2.4 7.9 94.2 1.2 3.0 53.7 0.7 1.5 
Mean 12.4 0.4 0.5 39.2 5.9 8.5 88.0 2.0 3.1 47.2 1.3 1.8 
σ 2.0 0.3 0.5 5.3 6.0 7.7 16.0 1.2 2.3 15.1 0.9 1.6 
p-value 
PS* IMPT* PS* IMPT* PS* IMPT* PS* IMPT* 
<0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
* Statistical significance detected using both Student’s t-test and Wilcoxon signed-rank test 
 
Table 3.17 Selected heart evaluation metrics for VMAT, PS, and IMPT plans. Abbreviations: 
V22.5Gy (RBE) = volume that receives at least 22.5 Gy (RBE); V30Gy (RBE) = volume that receives at 
least 30 Gy (RBE); NTCP = normal tissue complication probability. 
Patient 





VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT 
1 9.3 0.1 0.3 2.6 0.0 0.1 0.10 0.00 0.00 0.09 0.00 0.00 
2 11.4 0.4 0.3 6.8 0.2 0.1 0.48 0.01 0.01 0.40 0.00 0.00 
3 7.3 0.5 2.3 3.4 0.3 1.4 0.22 0.03 0.15 0.13 0.00 0.04 
4 10.2 - 0.0 5.2 - 0.0 0.48 - 0.00 0.51 - 0.00 
5 12.8 0.3 0.2 10.2 0.1 0.1 1.77 0.02 0.00 2.12 0.00 0.00 
6 17.0 1.6 0.9 11.3 1.0 0.3 1.85 0.17 0.02 1.92 0.01 0.00 
7 14.7 0.3 0.2 7.7 0.1 0.1 0.65 0.01 0.00 0.50 0.00 0.00 
8 14.2 0.2 0.3 9.1 0.1 0.1 1.02 0.01 0.00 1.10 0.00 0.00 
Mean 12.1 0.5 0.6 7.0 0.3 0.3 0.82 0.04 0.02 0.85 0.002 0.005 
σ 3.2 0.5 0.8 3.1 0.3 0.5 0.67 0.06 0.05 0.79 0.005 0.014 
p-value 
PS* IMPT* PS* IMPT* PS* IMPT* PS* IMPT* 
<0.001 <0.001 0.001 0.001 0.017 0.014 0.019 0.020 





3.2.4 Contralateral Breast  
Table 3.18 lists the evaluation metrics for the contralateral breast for each patient. A 
statistically significant difference was found in  ̅     and  ̅    for both proton modalities when 
compared to VMAT (p < 0.001).  ̅     for VMAT was 7.3±2.5 Gy, 0.2±0.1 Gy (RBE) for PS, 
and 0.3±0.2 Gy (RBE) for IMPT. VMAT had the highest  ̅    at 22.0±5.9 Gy. IMPT had the 
next highest  ̅    at 5.6±3.0 Gy (RBE), and PS had the lowest at 1.4±1.6 Gy (RBE). The 
volume of the contralateral (right) breast receiving 5 Gy (RBE) or more was statistically 
significantly lower using both proton techniques (p ≤ 0.001).  ̅   (   ) for VMAT was 
56.9±23.5% which was 57 times higher than that from PS and 28.4 times higher than that from 
IMPT. Patient averaged SCCP for VMAT was 3.89%±1.41% and was statistically significantly 
lower for PS (0.12±0.06%) and IMPT (0.20±0.09%) with p < 0.001. 
 
Table 3.18 Selected contralateral breast evaluation metrics for VMAT, PS, and IMPT plans. 
Abbreviations: Dmean = mean dose; Dmax = maximum dose; V5Gy (RBE) = volume that receives at 
least 5 Gy (RBE). 
Patient 
Dmean [Gy (RBE)] Dmax [Gy (RBE)] V5Gy (RBE) [%] SCCP [%] 
VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT 
1 8.7 0.0 0.2 22.8 0.0 4.1 73.0 0.0 1.6 4.63 0.03 0.14 
2 5.8 0.3 0.3 19.7 2.9 5.9 45.6 1.6 2.3 3.01 0.17 0.20 
3 10.3 0.1 0.6 30.8 0.3 10.9 71.7 0.8 3.3 5.70 0.09 0.37 
4 9.8 - 0.5 27.7 - 8.3 75.3 - 3.1 5.36 -  0.29 
5 4.1 0.1 0.1 11.1 0.2 1.7 28.1 0.5 0.6 2.06 0.06 0.08 
6 3.8 0.3 0.4 20.1 2.7 6.2 18.7 1.5 2.4 1.97 0.17 0.20 
7 7.8 0.1 0.3 23.8 0.2 4.9 61.0 0.7 2.0 4.15 0.09 0.19 
8 8.0 0.3 0.2 20.1 3.7 2.9 81.7 1.7 1.2 4.19 0.19 0.13 
Mean 7.3 0.2 0.3 22.0 1.4 5.6 56.9 1.0 2.1 3.89 0.12 0.20 
σ 2.5 0.1 0.2 5.9 1.6 3.0 23.5 0.6 0.9 1.41 0.06 0.09 
p-value 
PS* IMPT* PS* IMPT* PS* IMPT* PS* IMPT* 
<0.001 <0.001 <0.001 <0.001 0.001 <0.001 <0.001 <0.001 






Table 3.19 lists the mean, maximum, and minimum doses in the skin (5 mm shell) for 
each patient.  ̅     was statistically significantly lower for PS (p = 0.021) and IMPT (p = 0.006) 
versus VMAT; with of 50.9±0.3 Gy, 50.6±0.1 Gy (RBE), and 50.5±0.03 Gy (RBE) for VMAT, 
PS, and IMPT, respectively. There was a 1.2 Gy (RBE) difference between VMAT and IMPT 
for  ̅    (p < 0.001) with IMPT having a statistically significantly lower  ̅    at 51.7±0.3 Gy 
(RBE).  However, no statistically significant difference was detected between VMAT and PS for 
 ̅   . IMPT had a statistically significantly higher  ̅    (p = 0.046) than that for VMAT with 
values of 49.0±0.5 Gy (RBE) and 47.5±1.8 Gy for IMPT and VMAT, respectively. Again, no 
statistically significant difference was detected between VMAT and PS for  ̅   . 
Table 3.19 Selected skin (5 mm shell) evaluation metrics for VMAT, PS, and IMPT plans. 
Abbreviations: Dmean = mean dose; Dmax = maximum dose; Dmin = minimum dose; PS p-value = 
VMAT vs. PS; IMPT p-value = VMAT vs. IMPT.   
Patient 
Dmean [Gy (RBE)] Dmax [Gy (RBE)] Dmin [Gy (RBE)] 
VMAT PS IMPT VMAT PS IMPT VMAT PS IMPT 
1 50.9 50.6 50.5 53.5 52.4 51.5 46.1 47.9 49.4 
2 50.6 50.7 50.5 52.7 52.9 52.3 44.1 46.5 48.3 
3 50.7 50.7 50.6 52.5 52.4 51.5 48.2 48.1 49.5 
4 51.6 - 50.6 53.5 - 51.6 49.4 - 49.2 
5 51.0 50.5 50.6 52.7 52.6 51.7 48.6 45.9 48.7 
6 51.0 50.7 50.5 53.1 52.3 51.9 48.4 47.8 48.4 
7 50.9 50.7 50.5 52.4 52.4 51.5 48.9 48.5 49.3 
8 50.9 50.5 50.6 53.1 52.0 51.6 46.5 47.8 48.9 
Mean 50.9 50.6 50.5 52.9 52.4 51.7 47.5 47.5 49.0 
σ 0.3 0.1 0.03 0.4 0.3 0.3 1.8 0.9 0.5 
p-value 
PS** IMPT* PS IMPT* PS IMPT* 
0.021 0.006 0.086 <0.001 0.724 0.046 
* Statistical significance detected using both Student’s t-test and Wilcoxon signed-rank test  






3.2.6 NTCP and SCCP Sensitivity Analysis 
Figure 3.18 plots the patient averaged normal tissue complication probabilities (    ̅̅ ̅̅ ̅̅ ̅̅ ) 
for various values of model parameters s, γ, and D50 for the whole heart and myocardium for 
each PMRT technique.     ̅̅ ̅̅ ̅̅ ̅̅  for the whole heart ranged from 0.1% to 2.1% for VMAT when 
the seriality parameter (s) was varied between 0.46 and 1.54 (Johansson et al., 2002) with γ = 
1.28 and D50 = 52.3 Gy.     ̅̅ ̅̅ ̅̅ ̅̅  values for the same set of parameter values (s = 0.46 to 1.54; γ = 
1.28; and D50 = 52.3 Gy) were lower for both proton modalities than VMAT with a range of 
<0.01 to 0.26 and <0.01 to 0.15 for PS and IMPT, respectively. When the slope from the dose-
response curve (γ) was varied between 0.8 and 2.00 (Johansson et al., 2002) with s = 1.00 and 
D50 = 52.3 Gy (RBE),     ̅̅ ̅̅ ̅̅ ̅̅  for the whole heart ranged from 3.1% to 0.25% for VMAT, 0.33% 
to 0.02% for PS, and 0.33% to 0.01% for IMPT. Similarly,     ̅̅ ̅̅ ̅̅ ̅̅  ranged from 1.58% to 0.34% 
for VMAT, 0.07% to 0.02% for PS, and 0.05% to 0.01% for IMPT when D50 varied between 
45.7 Gy (RBE) and 61.7 Gy (RBE) with s = 1.00 and γ = 1.28.  
When these     ̅̅ ̅̅ ̅̅ ̅̅  values were compared to the baseline     ̅̅ ̅̅ ̅̅ ̅̅  values for each 
technique, we saw an increase in predicted risk for higher s values and lower values of γ and D50, 
with the highest average predicted risk for γ =  0.8.  It was also observed that no matter the 
model parameter value that we considered, the predicted risk of excess cardiac mortality at 15 
years due to radiation therapy was consistently higher for VMAT compared to both proton 
modalities. Evidently, despite the model sensitivity to different parameter s values the qualitative 
findings from the baseline risk results (see section 3.2.3), i.e., that both proton modalities 
produced lower     ̅̅ ̅̅ ̅̅ ̅̅  in the whole heart compared to VMAT was insensitive to the risk 





Figure 3.18 Patient averaged NTCP (%) for various values of model parameters s, γ, and D50 for 
the whole heart (left) and myocardium (right) following VMAT (dash-dotted line), PS (solid 
line), and IMPT (dashsed line). Whole Heart: s varied between 0.46 and 1.54 with γ=1.28, 
D50=52.3 Gy (RBE). γ varied between 0.80 and 2.00 with s=1.00,D50=52.3 Gy (RBE). D50 varied 
between 45.7 and 61.7 Gy (RBE) with s=1, γ=1.28. Myocardium: s varied between 0.39 and 1.35 
with γ=1.25, D50=52.2 Gy (RBE). γ varied between 0.77 and 1.99 with s=0.87,D50=52.2 Gy 





Similar results were observed for the predicted risk of cardiac mortality in the 
myocardium.     ̅̅ ̅̅ ̅̅ ̅̅  for the myocardium ranged from 0.12% to 1.96% for VMAT when the 
seriality parameter was varied between 0.39 and 1.35 (Gagliardi et al., 2001) with γ = 1.25 and 
D50 = 52.2 Gy.     ̅̅ ̅̅ ̅̅ ̅̅  values for the same set of parameter values were considerably lower for 
both proton modalities than VMAT with a range of <0.01 to 0.03 for both PS and IMPT. When 
the slope of the dose-response curve (γ) was varied between 0.77 and 1.99 (Gagliardi et al., 
2001) with s = 1.00 and D50 = 52.2 Gy (RBE),     ̅̅ ̅̅ ̅̅ ̅̅  for the myocardium ranged from 3.97% to 
0.22% for VMAT, 0.40% to <0.01% for PS, and 0.43% to <0.01% for IMPT. Similarly,     ̅̅ ̅̅ ̅̅ ̅̅  
ranged from 1.68% to 0.35% for VMAT and <0.01% for both proton modalities when D50 varied 
between 45.4 Gy (RBE) and 61.6 Gy (RBE) with s = 1.00 and γ = 1.25 (Gagliardi et al., 2001). 
Again the model predicted the hightest NTCP values for lower values of γ for all techniques 
compared to the baseline NTCP estimates, with     ̅̅ ̅̅ ̅̅ ̅̅  being greatest for VMAT compared to the 
proton modalities. In fact,     ̅̅ ̅̅ ̅̅ ̅̅  was consistently higher for VMAT than PS and IMPT for all of 
the model parameter (s, γ, and D50) values. Again this was consistent with the earlier conclusion 
based off the baseline risk estimates (see section 3.2.3) that both proton modalities statisitcally 
significantly lowered the predicted risk of cardiac mortality (15 years) in the myocardiun 
compared to VMAT. 
NTCP of radiation pneumonitis for the lungs using the Lyman-Kutcher-Burman (LKB) 
model (see section 2.8.2) was also calculated for several different model parameter values for 
each PMRT technique. Figure 3.19 plots the patient averaged NTCP values (    ̅̅ ̅̅ ̅̅ ̅̅ ) for various 
values of model parameters n, m, and D50 for the lungs for each PMRT technique.     ̅̅ ̅̅ ̅̅ ̅̅  values 
for VMAT ranged from 3.9% to 1.2% when the volume effect parameter (n) was varied between 





Figure 3.19 NTCP (%) for various values of model parameter n, m, and D50 for the lungs, 
following VMAT (dash-dotted line), PS (solid line), and IMPT (dashsed line). n varied between 
0.6 and 2.8 with m=0.37, D50= 30.8 Gy (RBE). m varied between 0.28 and 0.56 with n=0.99, 





values were lower than VMAT for the same interval of n values, and ranged from 2.8% to 0.4% 
and 1.9% to 0.4%, respectively. Like the relative seriality model used for NTCP calculations in 
the heart, the LKB model was most sensitive to variations in the slope of dose-response curve 
(m) with the highest predicted risk occurring for larger slope values for all techniques.      ̅̅ ̅̅ ̅̅ ̅̅  
values for the lungs ranged from 0.4% to 8.8% for VMAT, 0.1% to 5.8 % for PS, and 0.1% to 
5.6% for IMPT, when m was varied between 0.28 and 0.56 with n = 0.99 and D50 = 30.8 Gy 
(RBE). When D50 was taken as 23 Gy     ̅̅ ̅̅ ̅̅ ̅̅  for VMAT was as high as 3.4% while both proton 
modalities were just above 1%. From these results, it was concluded that the LKB model was 
sensitive to parameter value selection for calculating the absolute risk for radiation pneumonitis 
(grade > 2) for each PMRT technique. However,     ̅̅ ̅̅ ̅̅ ̅̅  values for VMAT were consistently 
higher than each proton modality for each variation in the model parameter values used. This 
result was consistent with the earlier claim stated in section 3.2.2 that said PS and IMPT lowered 
the predicted risk of radiation pneumonitis compared to VMAT based off baseline estimates. 
Baseline estimates were calculated using the following model parameter values: n = 0.99, m = 
0.37 and D50 = 30.8 Gy and patient averaged NCCP for these values were plotted on Figure 3.19. 
Figure 3.20 plots the patient averaged SCCPs (absolute cancer incidence per lifetime) and 
standard deviations calculated using the linear, linear-exponential, and linear-plateau models for 
VMAT, PS, and IMPT for the contralateral breast.     ̅̅ ̅̅ ̅̅ ̅ using the linear (baseline) model was 
highest for VMAT at 3.9%±1.4% compared to <0.5% for both PS and IMPT. Similarly,     ̅̅ ̅̅ ̅̅ ̅ 
values from the linear-exponential and linear-plateau models were highest for VMAT at 
2.0%±0.5% and 2.4%±0.7%, respectively. Both proton techniques statistically significantly 
reduced (p < 0.001)     ̅̅ ̅̅ ̅̅ ̅ compared to VMAT with a predicted risk of ≤0.1% calculated using 




higher for VMAT compared to each proton modality (p < 0.001) for all three different OED 
models, it was concluded that the ability of PS and IMPT to statistically significantly reduce the 
predicted risk of absolute cancer incidence per lifetime for the contralateral breast compared to 
VMAT was not dependent on the selection of models considered in this work. 
 
Figure 3.20 Patient averaged SCCP (±1σ) values for the contralateral breast following PMRT 
using VMAT, PS, and IMPT techniques calculated using linear, linear-exponential, and linear-
plateau dose-response models. 
 
Figure 3.21 plots the patient averaged SCCPs (absolute cancer incidence per lifetime) and 
standard deviations calculated using the linear, linear-exponential, and linear-plateau models for 
VMAT, PS, and IMPT for the lungs. VMAT had the largest     ̅̅ ̅̅ ̅̅ ̅ at 12.5%±0.88% when the 
linear dose model was used. 4.1% and 5.3%     ̅̅ ̅̅ ̅̅ ̅  values were found when the linear-
exponential and linear-plateau models were used to calculate SCCP for the VMAT plans. The PS 
proton technique had     ̅̅ ̅̅ ̅̅ ̅ values of 5.9%, 0.7%, and 1.4% when the linear, linear-exponential, 
and linear-plateau models were used, respectively, and were statistically significantly lower than 























and linear-plateau models were 5.6%, 1.3%, and 1.9%, respectively, and were also statistically 
significantly lower than values predicted for VMAT (p < 0.001) for each model. Since     ̅̅ ̅̅ ̅̅ ̅ 
was statistically significantly higher for VMAT compared to each proton modality (p < 0.001) 
for all three different OED models, it was concluded that the ability of PS and IMPT to 
statistically significantly reduce the predicted risk of absolute cancer incidence per lifetime for 
the lungs compared to VMAT was not model dependent. 
 
Figure 3.21 Patient averaged SCCP (±1σ) values for the lungs following PMRT using VMAT, 
PS, and IMPT techniques calculated using linear, linear-exponential, and linear-plateau dose-
response models. 
 
Table 3.20 lists the mean, standard deviation, and p-value of RNTCP for the lung, heart, 
and myocardium along with RSCCP for the lung and contralateral breast. RNTCP and RSCCP 
were calculated for both proton techniques separately. A value of 1.0 indicated no change in risk 
from photon PMRT to proton PMRT, a value above 1.0 indicated an increase in risk from the 
proton modalities, and a value less than 1.0 indicated a decrease in predicted risk from the proton 
























1.0 for both proton modalities, signifying an advantage for both proton PMRT techniques to 
lower predicted risks to the lungs, heart, and contralateral breast. These findings are consistent 
with the earlier absolute risk observations noted in sections 3.2.2 through 0. 
 
Table 3.20 Average predicted RNTCP and RSCCP for cardiopulmonary structures and the 
contralateral breast based on baseline model parameters. Blanks in RNTCP column indicate 
organs that did not use an NTCP model. Blanks in RSCCP column indicate organs that did not 
use an SCCP model. P < 0.05 was statistically significant. 
  
Ratio of PS and VMAT Ratio of IMPT and VMAT 
Structure RNTCP RSCCP RNTCP RSCCP 
Lung 
Mean 0.43 0.46 0.40 0.45 
σ 0.15 0.20 0.09 0.13 
p-value <0.001 <0.001 <0.001 <0.001 
Heart 
Mean 0.04 - 0.09 - 
σ 0.05 - 0.24 - 
p-value <0.001 - <0.001 - 
Myocardium 
Mean 2.34E-03 - 0.04 - 
σ 3.55E-03 - 0.11 - 
p-value <0.001 - <0.001 - 
Contralateral 
Breast 
Mean - 0.04 - 0.05 
σ - 0.03 - 0.02 





Chapter 4 Discussion 
This study compared passively scattered proton therapy (PS) and intensity modulated 
proton therapy (IMPT) to volumetric modulated arc therapy (VMAT) for a clinically 
representative sample of 8 left-sided breast cancer patients treated with post-mastectomy 
radiotherapy. The goals of this study were to reduce the dose to the surrounding normal tissues 
while maintaining equal or better PTV dose coverage for both re-planning proton techniques; 
calculate the corresponding predicted risk of radiogenic second cancers and normal tissue 
complications; estimate the uncertainties in the predicted dosimetric and radiobiological metrics, 
and to test for statistically significant predicted differences between the photon and proton 
modalities. The hypothesis of the study was that for a clinically representative cohort of post-
mastectomy patients, passively scattered and intensity modulated proton therapy could improve 
predicted normal tissue sparing while maintaining equal or better target coverage than volumetric 
modulated arc therapy photon plans, ultimately resulting in statistically significantly lower (p < 
0.05) predicted risks of several late effects for the heart, lungs, and contralateral breast. The 
baseline results of this study support the hypothesis for both passively scattered and intensity 
modulated proton therapy. Specifically, PS and IMPT significantly lowered average predicted 
risks for the sample. A sensitivity analysis of patient setup error reinforced the qualitative 
baseline findings of this study for up to a 0.5 cm isocenter shift, and a sensitivity analysis of 
proton range uncertainty confirmed the baseline qualitative findings to be robust up to a ±10% 
HU to proton linear relative stopping power conversion error. A sensitivity analysis of lung 
NTCP and heart NTCP model parameter selection found that the average NTCP values for PS 
and IMPT were consistently lower than that of VMAT for different risk model parameter values. 




also found that the average SCCP values for PS and IMPT were consistently statistically 
significantly lower than that of VMAT for different OED models. Both sensitivity analyses’ 
results were consistent with the baseline NTCP and SCCP findings. 
The major outcomes of this work are summarized in sections 4.1 through 4.3, followed 
by the significance, strengths, weaknesses, and possible future research directions. 
 
4.1 Outcomes of Specific Aim One 
Aim one determined if certain PTV and OAR dose-volume metrics were statistically 
significantly different between VMAT and both proton modalities for the sample. To accomplish 
this, PS and IMPT treatment plans were created for PMRT. Out of the eight patients selected for 
this work, seven were planned with PS and eight were planned with IMPT. All proton plans met 
the dosimetric planning goals when normalized to the mean evaluation PTV dose, and all were 
approved by the same radiation oncologist who approved the original VMAT plan. VMAT plans 
met most dosimetric planning goals. Five of the eight patients treated with VMAT did not meet 
the goal of D95% ≥47.8 Gy. However, these objectives were meant to be conservative, and a 
radiation oncologist deemed each of the VMAT plans clinically acceptable and the patients were 
thus treated. 
Both proton plans showed statistically significantly better PTV conformity and dose 
homogeneity (p < 0.05) compared to VMAT. As expected and by design, no statistically 
significant difference was observed for tumor control probability, since all treatment techniques 
had nearly 100% TCP.  Both proton modalities were able to statistically significantly reduce the 
volume of the heart, lungs, and contralateral breast receiving dose. These results strongly suggest 
that either PS or IMPT for the treatment of subclinical disease after a mastectomy would be 




patients would include those with prior/current cardiopulmonary complications or unfavorable 
anatomy since they are already at an increased risk of cardiovascular diseases (Weber et al., 
2006). 
Because skin is an oncologic target of treatment for post-mastectomy patients, erythema is 
expected with any radiotherapy technique. The doses reported to the skin (5 mm shell) were 
similar between PS, IMPT, and VMAT with doses just above the prescription dose. However, 
the skin received a statistically significantly higher maximum dose when treated with VMAT 
than IMPT, with no observed statistically significant difference between VMAT and PS. The 
mean dose to the skin was also closer to the desired prescribed dose of 50.4 Gy (RBE) for both 
proton modalities.  A recent study (Macdonald et al., 2013b) assessed acute skin toxicity for 12 
post-mastectomy patients treated with two matched passively scattered proton fields. Skin 
reactions were mostly superficial and often with moderate to severe erythema and moderate to 
large areas of dry superficial desquamation. After 4 to 8 weeks cosmesis was favorable and 
patients only had mild erythema.  
The dosimetric results agreed well with previous photon and proton treatment planning 
comparisons for breast cancer patients. In a study by Ares et al. (2010), IMPT improved target 
coverage and reduction of low doses to OARs for complex-target whole breast irradiation for 
breast cancer patients when compared to static field IMRT and three-dimensional conformal 
radiotherapy (3D-CRT). In another study, passively scattered proton therapy decreased dose to 
surrounding normal structures without compromising target coverage for a cohort of post-








4.2 Outcomes of Specific Aim Two 
Specific aim two predicted and compared the absolute risk of radiation pneumonitis Grade 
2 or greater at 6 months, excess cardiac mortality at 15 years, and radiogenic second cancer 
incidence per lifetime for patients planned with VMAT, PS, and IMPT and compared the 
corresponding risks. NTCP models are important tools for estimating complication risks. In some 
clinical sites, however, the complication events used to deduce the dose-response curves are 
infrequent, which has limited confidence to use NTCP estimates for clinical decision making. 
Until additional clinical data are available to validate the predictive models, NTCP estimates are 
best used for relative comparison between techniques rather than for absolute risk assessment 
(Pierce et al., 2002). That being said, predicted risks investigated within this study were 
statistically significantly reduced for both proton modalities when compared to VMAT. The 
predicted risks between the two proton techniques were not statistically different from one 
another. 
 The average NTCP for the lung with radiation pneumonitis (RP) Grade 2 or higher was 
2.05%±0.23%, 0.91%±0.39%, and 0.83%±0.22% for VMAT, PS, and IMPT, respectively. These 
values fall within previously reported clinical incidence of 1 to 5% following breast cancer 
radiotherapy (Marks et al., 2010). Both proton therapy modalities significantly reduced the risk 
of RP, which was supported by a similar study by Johansson et al. (2002) which compared 
passively-scattered proton beams, static field IMRT (6-beams), mixed electron-photon, and 
photon tangential techniques for node-positive left-sided breast cancer patients after breast-
conserving surgery. They found a mean NTCP value of 0.6±0.8% using the relative seriality 
model following proton therapy which was significantly lower than all other techniques 




helical tomotherapy and VMAT for the risk of RP computed using the Lyman-Kutcher-Berman 
model using the following values: D50=24.5 Gy, n=0.87, and m=0.18. No significant difference 
between the two modalities was found, with an average NTCP value of 0.3%±0.1% for VMAT 
plans and 0.6%±0.1% for HT plans. These values do not agree with the 2.05%±0.23% risk 
estimated for VMAT within this study even though  ̅     to the lungs was similar between the 
two studies. Disagreement in average NTCP values may be attributed to the variation in model 
parameter values used. The parameter values used in this study are from a more recent 
publication (Seppenwoolde et al., 2003) than the one used in the study by Nichols et al. (2014). 
The average baseline SCCP values for the lungs were 12.5%±0.9% in VMAT, 5.9%±2.9% 
in PS and 5.61%±1.81% in IMPT. Average SCCP values using the linear-exponential model in a 
PMRT study by Nichols et al. (2014) predicted a value of 5.3%±0.1% for VMAT. We had a 
similar result at 4.1%±0.6% for VMAT using the linear-exponential model as well. SCCP results 
represent lifetime risk, with a mean residual lifetime of 50 years. Smoking at the time of 
radiation or earlier increased the 15-year risk of developing a lung cancer after breast conserving 
surgery and radiation by 6% and 4.7%, respectively compared to 0.26% for non-smokers 
(Obedian et al., 2000). Beside the inherent increased risk in cancer survivors due e.g. lifestyle, 
both chemotherapy and radiotherapy are known to further increase the risk of second solid 
cancers (Abo-Madyan et al., 2014). The proportion of risk attributed to radiotherapy alone has 
been variably reported and to date there are no clinical analyses reporting second cancer 
induction after VMAT or proton PMRT due to the limited time span of its clinical availability.  
 Average NTCP values for the whole heart were 0.82%±0.67%, 0.04%±0.06%, and 
0.02%±0.05% for VMAT, PS, and IMPT, respectively. In a previous study, Johansson et al. 




treatment using passively scattered proton therapy for 11 patients. They reported a value of 
0.5%±0.5% calculated using the relative-seriality model for a single LAO proton field. The PS 
results from our study agreed well with their findings. Our average NTCP values for the 
myocardium were highest for VMAT with 0.85%±0.79% and nearly 0% for both proton 
modalities. Several previous studies have found protons to be advantageous for the reduction of 
heart irradiation and late toxicity for breast cancer radiotherapy (Weber et al., 2006; Ares et al., 
2010). The predicted decrease in cardiac mortality when using protons for post-mastectomy 
radiotherapy will not be observed until after a long follow-up (15 years) (Pierce et al., 2002). 
Studies that report an increased risk of non-breast cancer deaths from myocardial infarction and 
ischemic heart disease after irradiation did not see these effects until 10 or more years after 
exposure (Rutqvist et al., 2003; Darby et al., 2013).  
No excess breast cancer risk has been found among women irradiated at age 40 years or 
older. Boice et al. (1992) showed radiation exposure after the age of 45 years entails little, if any 
risk (relative risk, 1.01) of radiation-induced breast cancer for a female population of an average 
age of 51.7 years exposed with mean radiation dose of 2.51 Gy to the contralateral breast. 
Therefore, the risk of contralateral breast cancer after radiotherapy for breast cancer appears to 
be limited to women who are younger than age 40 to 45 years (premenopausal) at exposure, and 
highest for PMRT patients (Travis et al., 2011). In the current study, the average age for the 
eight patients was 54. Both proton modalities were able to significantly reduce the mean dose to 
the contralateral breast and SCCP compared to VMAT. The patient averaged SCCP using the 
linear dose-risk model for VMAT was 3.89%±1.41%, 0.12%±0.06% for PS, and 0.20%±0.09% 
for IMPT. It was expected for both proton modalities to produce statistically significantly lower 




 ̅     values. Nichols et al., (2014) reported an average SCCP value of 1.0% for VMAT using 
the linear-exponential dose-response model. This value was similar but lower than our result of 
2% using the same model. SCCP results for the contralateral breast represent lifetime risk, with a 
mean residual lifetime of 50 years. Therefore, the results of our study are especially important 
for younger patients, whose longer residual lifetime puts them at great risk for radiogenic second 
malignancies. 
4.3 Outcomes of Specific Aim Three 
The goal of aim three was to determine the impact of patient setup errors, proton range 
errors, and risk model choice had on DVH and predicted risk values. In general, patient setup 
errors tend to cause geometric misalignment of the treatment field, resulting in inadequate target 
coverage. An isocenter shift of 1 cm in any direction for VMAT and IMPT for the representative 
patient (CW-3) caused a large degradation in PTV dose coverage. PS was less susceptible to set-
up errors and this was largely in part to compensator smearing. It should be noted that in current 
treatment practice, a patient set-up error of 1 cm is an extreme case but still within a plausible 
misalignment range. For example, the commonly used vacuum bags in lung cancer treatments 
can introduce over 1 cm variations in the thickness of soft tissue around the chest wall: and 
breast position in female patients can introduce additional thickness variations. It is therefore 
common that no such vacuum bag immobilization devices are used for treatment of tumors in the 
thorax region using proton therapy and beams that enter female patients through breasts are 
minimally used (Li, 2012). However, some set-up errors are random and can be averaged out by 
repainting dose (IMPT) and fractionating treatments over the course of treatment (Wang et al., 




all plans. SCCP for the lungs was impacted the most, but didn’t deviate more than 4% from the 
nominal risk predication for either modality.  
The uncertainty margins used for proton planning incorporated both set-up errors and 
errors in CT number to proton linear relative stopping power. The latter error was investigated 
separately from the patient set-up errors by simulating a 3.5% and 10% error in relative linear 
proton stopping power conversion. This simulation for a single patient indicated PS and IMPT 
plans are robust for up to a 10% error. The evaluation PTV maintained adequate dose coverage 
and predicted risk of late effects had small changes <1.2% from the nominal dose distribution for 
both PS and IMPT. 
Upon a sensitivity analysis for NTCP parameter values for the Lyman-Kutcher-Burman 
model (radiation pneumonitis) and the relative seriality model (cardiac mortality); we quantified 
how the absolute risk for each organ (lungs and heart) was dependent on model parameter 
selection. We found that the models were most sensitive to variations in the slope of the dose-
response curve for each technique. The average NTCP values for PS and IMPT were consistently 
lower than that of VMAT for different risk model parameter values. This same result was 
observed for SCCP when different dose-risk models were investigated for the contralateral breast 
and the lungs. The differences obtained in this study between the linear, linear-exponential, and 
linear-plateau dose-risk models for SCCP were most pronounced for VMAT plans. This was due 
to the fact that the linear model deviates from the other two models for doses larger than about 5 
Gy (RBE) (Abo-Madyan et al., 2014). Dose to the contralateral breast and lungs was 
considerably higher in the VMAT plans and thus the deviations between the linear model and 




 Two different case-control studies of female breast cancer following treatment for 
Hodgkin lymphoma before age 30 years (Travis et al., 2003) and in childhood cancer survivors 
(Inskip et al., 2009), found the risk of breast cancer increased with increasing radiation dose to 
the breast, reaching an odds ratio of 8 or more at doses of 40 Gy or more with no evidence of a 
downturn in the risk of breast cancer at the highest doses. These studies support the use of the 
linear OED model for the calculation of SCCP for the contralateral breast. However, there are 
also studies that show a reduced risk of breast cancer with increasing dose or linear-exponential 
dose-response model. This effect is due to treatment-related premature menopause for a radiation 
dose to the ovary exceeding 5 Gy (RBE) (Travis et al., 2011). Therefore, the absolute risks of 
contralateral second cancer predicted using the linear and linear-exponential models within this 
study are both relevant and when used together provide a more robust conclusion about which 
technique would be appropriate for patients. 
4.4 Implications and Significance of the Results 
In treating post-mastectomy disease, the planning complexity is increased by many factors, 
such as the high dose prescribed to the tumor and the simultaneous irradiation of regional lymph 
nodes. The large and complex shaped PTV entail the involvement of many OARs whose dose 
tolerances are limiting factors for post-mastectomy radiotherapy. Thanks to its innovative 
delivery characteristic, VMAT plans provide a very conformal dose distribution tailored to the 
planning target volume, minimizing the dose to selected OARs, but unfortunately spreading out 
the dose over a large volume of non-target tissues. Because of their finite and energy-dependent 
range protons improved the dose distributions outside of the PTV, reducing acute and late 




Cardiac toxicity has been implicated as the primary reason for excess non-breast cancer 
mortality in early breast cancer studies (Senkus-Konefka and Jassem, 2007). Studies of PMRT 
utilizing more modern techniques and fractionation schedules have demonstrated survival 
benefits and no increase in cardiac mortality (Nixon et al., 1998; Hojris et al., 1999; Correa et 
al., 2007). However, the increasing use of cardiotoxic chemotherapy agents such as Doxorubicin 
and Trastuzumab, adds another confounding factor to determining the effect of radiation therapy 
on cardiac outcomes (Macdonald et al., 2013a). Dose to the heart should therefore be minimized 
as much as possible. In this study, passively scattered and intensity modulated proton therapy 
techniques for post-mastectomy patients were able to significantly reduce dose to the heart and 
subsequently the predicted risk of cardiac mortality in both the whole heart and myocardium 
structures.  
Other normal tissue complications that arise from breast cancer radiotherapy are radiation 
pneumonitis and radiogenic second cancers. While lung toxicity is less serious than cardiac 
mortality, it may be troublesome and disabling. Irradiation to the lungs to doses higher than 30 
Gy (RBE) may also result in fibrosis and reduced lung capacity (Johansson et al., 2002). The risk 
of a radiation-induced malignancy is relatively small, but considering the large number of 
patients treated and the gravity of a second malignancy, it should not be ignored. We showed a 
potentially significant decrease in the predicted risk of lung toxicity and second cancers with the 
use of either passively scattered and intensity modulated proton therapy for PMRT. 
 
4.5 Strengths and Limitations 
Our study has several strengths. First, we used realistic patient data and treatment plans 
system and detailed risk calculations. Second, we investigated passively scattered and intensity 




radiogenic second cancers based on recent dose-response models. Gagliardi et al. (2010) 
suggested that clinical outcomes of certain organs are better correlated when NTCP parameters 
are derived from the DVH of the same organ. Therefore, the inclusion of the myocardium 
contouring and DVH provided a more robust estimation of the potential clinical outcomes for the 
heart following VMAT, PS, or IMPT since the whole heart and myocardium risk estimates were 
similar. Finally, the sensitivity analysis increased confidence in the qualitative findings of this 
study. 
Our study also has several limitations. Only eight patients were used for this work and, 
although that provided satisfactory statistical power, more patient data would provide more 
statistical robustness. Our predicted risks were calculated using only the therapeutic doses. 
Including the stray dose may have changed the predicted outcomes. Another limitation is the 
inability of the treatment planning systems to accurately report doses out-of-field. Finally, this 
study did not investigate the effects of respiratory and cardiac motion on the nominal dose 
distribution. Ares et al. (2010) looked at this issue and concluded that the effects were small for 
en face proton beams because the beam is parallel to the organ motion. 
4.6 Future Work 
The inclusion of right-sided PMRT patients and/or patients who underwent an immediate 
breast reconstruction before PMRT is a potential next step for this work. Our methodology could 
be applied after modifications take into account proton range errors within metallic tissue 
expanders that are common for reconstructed patients. A treatment planning comparison based 
on a boarder spectrum of post-mastectomy patients will be helpful to generalize the results of 
this study to the whole population of post-mastectomy patients. Also, since VMAT is delivered 




interesting. In a treatment planning comparison study of proton arc therapy and VMAT for three 
prostate cancer patients, Rechner et al. (2012) found the predicted risk of second cancers 
following proton arc therapy was less than or approximately equal to the risk following VMAT. 
Another proton arc study demonstrated a potential role for proton arc therapy as an alternative to 
electron arc therapy when lung dose must be minimized (Sandison et al., 1997).  
Given that mastectomy with adjuvant radiotherapy is not the standard of care for early 
stage breast cancer according to the National Comprehensive Cancer Network (NCCN, 2014), it 
may be worthwhile comparing VMAT and proton therapy for these patients treated with breast 
irradiation following conservation surgery. Several comparative planning studies hypothesize 
that protons will provide a decrease in acute and late cardiopulmonary toxicities for patients 
requiring radiotherapy for advanced or left-sided breast cancer compared to conventional and 
IMRT photon techniques (Johansson et al., 2002; Lomax et al., 2003; Weber et al., 2006; Ares et 





Chapter 5 Conclusion 
The rationale for the use of protons to treat post-mastectomy radiotherapy patients is to 
decrease late cardiopulmonary toxicity without compromising the desired target coverage. The 
current study provides new evidence that the use passively scattered and intensity modulated 
proton therapy can significantly improve predicted normal tissue sparing while maintaining 
equal or better target coverage compared to volumetric modulated arc therapy for the treatment 
of left-sided post-mastectomy radiotherapy (PMRT). Thus, proton radiotherapy for PMRT can 
significantly reduce the calculated risk of radiation pneumonitis, cardiac mortality, and 
radiogenic second cancers of the heart and lungs compared to VMAT photon PMRT regardless 
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Appendix A: Isodose Distributions and Dose Volume Histograms 
 Isodose distributions along with the dose volume histograms for each patient within the 
sample population are displayed within this section. Color coding is consistent with methods 




Figure A.1 DVH for patient CW-1 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for PS (dashed line) and VMAT (solid line) 
 
































Figure A.2 DVH for patient CW-1 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for IMPT (dashed line) and VMAT (solid line) 
 
































Figure A.3 Isodose distribution for patient CW-1 for PS (top), VMAT (middle), and IMPT 
(bottom) treatment plans in transverse slice- designated by yellow line in sagittal view- 






Figure A.4 DVH for patient CW-2 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for PS (dashed line) and VMAT (solid line) 
 
 
Figure A.5 DVH for patient CW-2 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for IMPT (dashed line) and VMAT (solid line) 
 




























































Figure A.6 Isodose distribution for patient CW-2 for PS (top), VMAT (middle), and IMPT 
(bottom) treatment plans in transverse slice- designated by yellow line in sagittal view- 






Figure A.7 DVH for patient CW-4 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for PS (dashed line) and VMAT (solid line) 
 
































Figure A.8 Isodose distribution for patient CW-4 for VMAT (top), and IMPT (bottom) treatment 








Figure A.9 DVH for patient CW-5 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for PS (dashed line) and VMAT (solid line) 
 
 
Figure A.10 DVH for patient CW-5 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for IMPT (dashed line) and VMAT (solid line) 
 




























































Figure A.11 Isodose distribution for patient CW-5 for PS (top), VMAT (middle), and IMPT 
(bottom) treatment plans in transverse slice- designated by yellow line in sagittal view- 






Figure A.12 DVH for patient CW-6 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for PS (dashed line) and VMAT (solid line) 
 
 
Figure A.13 DVH for patient CW-6 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for IMPT (dashed line) and VMAT (solid line) 
 




























































Figure A.14 Isodose distribution for patient CW-6 for PS (top), VMAT (middle), and IMPT 
(bottom) treatment plans in transverse slice- designated by yellow line in sagittal view- 






Figure A.15 DVH for patient CW-7 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for PS (dashed line) and VMAT (solid line) 
 
 
Figure A.16 DVH for patient CW-7 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for IMPT (dashed line) and VMAT (solid line) 
 




























































Figure A.17 Isodose distribution for patient CW-7 for PS (top), VMAT (middle), and IMPT 
(bottom) treatment plans in transverse slice- designated by yellow line in sagittal view- 






Figure A.18 DVH for patient CW-8 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for PS (dashed line) and VMAT (solid line) 
 
 
Figure A.19 DVH for patient CW-8 comparing PTV (red), lungs (blue), heart (magenta), and 
breast (green) for IMPT (dashed line) and VMAT (solid line) 
 




























































Figure A. 20 Isodose distribution for patient CW-8 for PS (top), VMAT (middle), and IMPT 
(bottom) treatment plans in transverse slice- designated by yellow line in sagittal view- 
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